RDsaúde

(Convenience Translation into English from the Original Previously Issued in Portuguese)

Juntos por uma sociedade mais saudável

Raia Drogasil S.A.

Individual and Consolidated
Interim Financial Information
At June 30, 2026

Raia DROGASIL

stix HEALTHBiT uma empresa RDsaúde CUCO HEALTH impulso soluções de mídia RDsaúde amplimed

(Convenience Translation into English from the Original Previously Issued in Portuguese)

Contents

1. Operations 27
2. Presentation of quarterly information 29
3. New accounting procedures, amendments to and interpretations of standards 30
4. Material accounting practices 30
5. Cash and cash equivalents 31
6. Held-to maturity investments 31
7. Trade receivables 32
8. Inventories 33
9. Recoverable taxes 34
10. Investments 35
11. Property, plant and equipment 40
12. Intangible assets 44
13. Employee benefits 48
14. Suppliers 48
15. Liabilities with senior shareholders 49
16. Borrowings and debentures 50
17. Leases 55
18. Provision for contingencies and judicial deposits 59
19. Income tax and social contribution 61
20. Earnings per share 63
21. Equity 64
22. Net sales revenue 67
23. Information on the nature of expenses recognized in the statement of income 68
24. Other operating income or expenses, net 69
25. Finance income (costs) 70
26. Financial instruments and risk management policy 71

27. Transactions with related parties 75
28. Insurance coverage 78
29. Non-cash transactions 78
30. Discontinued operations – Sale of 4Bio 78

Opinions and representations

Independent Auditor's Report on the Interim Financial Information 82
Comments on Business Projections Performance 84
Supervisory Board's Opinion 85
Officers' Representation on the Quarterly Information 86
Officers' Representation on the Independent Auditor's Report 87

(Convenience Translation into English from the Original Previously Issued in Portuguese)

São Paulo, August 04, 2026. RD Saúde (Raia Drogasil S.A. – B3: RADL3) announces its results for the 2nd quarter of 2026 (2Q26). The Company's parent company and consolidated financial statements for the periods ended June 30, 2026 and 2025 have been prepared in accordance with the accounting practices adopted in Brazil, including the rules issued by the Brazilian Securities Commission (CVM), the Brazilian Accounting Standards – General Technical (NBC TG) and the pronouncements issued by the Brazilian Accounting Pronouncements Committee (CPC), and are in conformity with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), and provide all the significant information related solely to the financial statements, which is consistent with the information used by management. The financial statements were prepared in Reais and all growth rates, unless otherwise stated, relate to the same
period of the previous year.

IFRS 16: Our financial statements are prepared in accordance with IFRS 16. To better reflect the economic reality of the business, the figures presented in this report consider the pre-IFRS 16 standard with a reconciliation available in a dedicated section of this document.

HIGHLIGHTS:

- **PHARMACIES: 3.687 units in operation with 76 openings and 3 closures in the quarter;**
- **GROSS REVENUE: R$ 12.8 B, +18.3% growth and +10.9% MSSS, +8.1 pp above CMED;**
- **MARKET SHARE: 19.7% national share, a +1.7 pp increase with gains in every region;**
- **DIGITAL: R$ 3.9 B, +52.2% growth and retail penetration of 31.0%;**
- **ADJ. EBITDA: R$ 1.0 B, +17.9% & stable margin of 8.0%;**
- **ADJ. NET INCOME (WITH 4BIO)*: R$ 433 MM, +7.4% & margin of 3.4% (-0.3 pp);**
- **CASH FLOW: R$ 550 MM positive free cash flow, R$ 1,190 MM total cash generation incl. 4Bio;**
- **FINANCIAL LEVERAGE: 0.8x ND/EBITDA, a 0.5x YoY reduction.**

** Includes the effects of taxation on investment subsidies, in accordance with the Law 14,789/2023.*

RADL3
R$ 18.85/share
Closing: Aug 03, 2026

MARKET CAP
R$ 33,0 billion

NUMBER OF SHARES
1,752,367,344

IR TEAM:
Flávio Correia
André Stolfi
Victor Torres
Felipe Correa

ir.rdsaude.com.br
ri@rdsaude.com.br

New consolidated summary (ex-4Bio)

In R$ thousands	2Q25	3Q25	4Q25	1Q26	2Q26
# of pharmacies	**3,371**	**3,453**	**3,547**	**3,614**	**3,687**
Organic openings	70	88	97	68	76
Closures	-	(6)	(3)	(1)	(3)
Headcount (EoP)	67,114	69,860	73,388	75,190	75,594
Pharmacist count (EoP)	13,734	13,981	14,377	14,965	15,199
# of tickets (thousands)	110,733	111,543	114,731	111,849	119,305
# of active customers (MM)	50.3	51.0	51.7	52.3	52.8
Gross revenue	**10,803,986**	**11,347,942**	**12,186,767**	**11,979,521**	**12,777,743**
Growth (YoY)	+13.1%	+15.5%	+22.3%	+20.4%	+18.3%
Gross profit	3,133,833	3,257,291	3,508,601	3,392,636	3,696,071
% of gross revenue	29.0%	28.7%	28.8%	28.3%	28.9%
Adjusted EBITDA	**862,980**	**892,592**	**924,318**	**820,786**	**1,017,348**
% of gross revenue	8.0%	7.9%	7.6%	6.9%	8.0%
Adj. net income (w/ 4Bio)	**402,744**	**401,986**	**361,654**	**299,752**	**432,729**
% of gross revenue	3.7%	3.5%	3.0%	2.5%	3.4%
Free cash flow	**(60,837)**	**615,609**	**(466,520)**	**284,869**	**549,989**

STORE DEVELOPMENT

Pharmacy count



	2Q25	3Q25	4Q25	1Q26	2Q26	LTM
Gross openings	**+70**	**+88**	**+97**	**+68**	**+76**	**+329**
Closures	-	-6	-3	-1	-3	-13
- Maturing	-	-	*-1*	-	-	*-1*
- Mature	-	*-6*	*-2*	*-1*	*-3*	*-12*
Net openings	**+70**	**+82**	**+94**	**+67**	**+73**	**+316**

Pharmacy portfolio

Age structure



We ended the 2Q26 with a total of 3,687 pharmacies in operation, opening 76 new units in 2Q26 and 329 LTM. We reiterate our guidance of 330-350 gross openings for 2026.

We closed 3 units in 2Q26 totaling 13 LTM, with only 1 still in the maturation process. This equates to a low error ratio of 0.3% of the LTM openings, highlighting the precision of our expansion process. The remaining 12 LTM closures were of mature units with an average of 13 years of operation, a result of the optimization of our portfolio, transferring revenues to our remaining nearby locations, releasing assets for efficient redeployment and eliminating fixed costs, thus increasing both the Company's EBITDA and ROIC.

At the end of 2Q26, a total of 25.0% of our pharmacies were still maturing and had not yet reached their full potential both in terms of revenue and profitability.

Number of cities with pharmacies



Pharmacies by region



Pharmacies by format



Our expansion continues to diversify our pharmacy network, both geographically and demographically. We have extended our presence to 684 cities in every state, +42 vs. the prior year, a unique capillarity in Brazilian retail under direct management.

We maintained a consistent expansion pace in São Paulo, our largest market, sustaining 32% of last year's expansion plan. Even with our broad presence in the state, we continue to identify meaningful opportunities and see solid performance from newly opened stores, reinforcing the potential to grow profitably across the country.

Finally, the IRR of new stores has been increasing, reflecting greater accuracy in expansion decisions, supported by recent efficiency gains in operations, by omnichannel performance, by the emerging GLP-1 market, among other factors.

Geographic presence



Retail Market Share



Source: IQVIA. Southeast excludes SP.

Our 3.7 thousand pharmacies are present in every state in the country and supported by an integrated network of 16 distribution centers, including the opening of the new DC in Itupeva/SP in April. This logistics grid allows us to serve more than 80% of our locations daily with lead times of up to 24 hours. As a result, we sustain high service levels, optimize working capital, and strengthen operational efficiency, establishing a significant competitive advantage.

Our national market share reached 19.7% in 2Q26, a robust gain of +1.7 pp vs. the prior year. In addition, we recorded relevant gains across all regions, demonstrating our competitive strength in diverse contexts and markets. Market shares reached 34.3% in São Paulo (+2.4 pp), 14.3% in the Southeast (+1.4 pp), 25.1% in the Midwest (+2.4 pp), 11.8% in the South (+0.7 pp), 14.4% in the Northeast (+1.4 pp), and 12.6% in the North (+1.6 pp).

We also achieved significant market share gains across all regions when excluding GLP-1 items and their substantial benefit to our figures.

DIGITAL, HEALTH AND CUSTOMER ENGAGEMENT

Digital sales and penetration



Digital channel mix



81 de NPS
App rating
R$ 14.1 B
LTM digital sales

Delivery mix



81 NPS
Delivery rating
1.1 B visits
Via apps and website LTM

We continued to advance our digital strategy, further strengthening our relationship with the customer. In the last 12 months, we recorded 1.1 billion visits across our digital channels, an impactful audience that enhances our role in promoting health. In addition, digitalization increases spending per customer, with digitally engaged loyal customers spending 30% more than the average loyal customer.

As a result, our digital channels reached R$ 3.9 billion in gross revenue in 2Q26, an absolute increase of R$ 1.4 billion and growth of +52% vs. the prior year. The share of digital channels reached 31.0% of retail sales, an increase of +6.1 pp.

We highlight the growing use of our apps, ensuring that customers enjoy the best mobile experience specialized in omnichannel health and wellness journeys. Digital sales through this channel increased +60% vs. the prior year, reaching an 83% share (+4 pp) of digital sales in the quarter.

This evolution in customer digitalization, leveraging our modern and proprietary channels, reflects the ongoing improvement of our mobile experience and a more complete, fully omnichannel health journey. It capitalizes on the capillarity of our store network, which has 95% of the A-Class population within a 1.5 km radius. This growing proximity, strengthened by our profitable organic expansion, constitutes another important competitive advantage by enabling 96% of digital orders to be delivered or picked up in less than 60 minutes with high economic efficiency.

Stix is another important source of differentiation through its customer loyalty ecosystem. We concluded on July 02, 2026 the acquisition of the remaining 67% of the company for R$ 23 million, with the first installment of R$ 2.3 million paid on the signing of the deal (May 20, 2026) and the remaining R$ 20.7 million on the closing of the deal (July 02, 2026). RD Saúde now holds 100% of Stix, ending its joint venture with GPA, but retaining them as a partner in the program. Founded in 2018, Stix has included RD Saúde as a minority shareholder with a 33.33% stake since 2019.

Stix operates in the structuring, development, operation and management of a loyalty program that brings together multiple partners and enables the accumulation, management and redemption of loyalty points. Stix is Brazil's largest customer loyalty ecosystem, ending 2Q26 with over 9.000 partner points of sale and a presence in every state. The coalition benefitted 15.0 million active customers in the last 12 months, with 6.7 million of them navigating within 2 or more partners. The acquisition of the company is aligned with RD Saúde's strategy to strengthen customer loyalty and engagement initiatives, while also simplifying Stix's corporate structure.

Finally, we continued to strengthen the role of our pharmacies in customers' integral health journey, positioning them as health hubs within the communities we serve and expanding engagement through pharmaceutical services. We now have 3.1 thousand units with *Mais Saúde* hubs and their expanded services portfolio, in addition to 442 units enabled for vaccination. In 2Q26, more than 1.9 million pharmaceutical services were performed, including CATs (clinical analysis tests), vaccinations, and other services, recording an NPS superior to the pharmacy average of 91.

GROSS REVENUES

Consolidated gross revenues



Retail sales mix



In a quarter without calendar effects, we ended 2Q26 with R$ 12,778 million in gross revenue, an 18.3% growth vs. the prior year.

We sustained a robust performance across all categories. Branded Rx grew +24.3% in the quarter, mainly driven by GLP-1 products. We highlight that the recent launching of new products in this category improves customer accessibility with volumes offsetting the reduction in average prices. Meanwhile, the other categories displayed a balanced performance among themselves: Generics grew +14.5%, OTC +13.0% and HPC +13.8% with a sequential acceleration of +2.1 pp vs. 1Q26.



Finally, we recorded average same-store sales growth of +12.5% in 2Q26. Among mature stores, which completed the full 3-year ramp-up, we posted an average growth of +10.9%, a pace 8.1 pp above the 2.8% CMED price adjustment authorized in 2026 and 6.3 pp above the LTM CPI. We highlight that, aligned with the market share gains, mature-store performance was robust in all regions, underscoring the elevated competitiveness of our brands within the different market environments.

GROSS PROFIT



* Includes the effects of taxation on investment subsidies, in accordance with the Law 14,789/2023.

Gross profit totaled R$ 3,696.1 million in the quarter, equivalent to a gross margin of 28.9%. We recorded a 0.1 pp contraction vs. the prior year, driven by the higher penetration of GLP-1 products that carry a structurally lower gross margin, by the non-cash NPV adjustment, and by the lower annual inflationary gains on inventories, stemming from the lower average price adjustment authorized by CMED in 2026 (2.8%) vs. 2025 (3.1%). These pressures were almost entirely offset by commercial gains and by momentarily higher inventory losses in the 2Q25 comp base.

SELLING EXPENSES



Selling expenses totaled R$ 2,370.4 million in 2Q26, equivalent to 18.6% of gross revenue, a 0.2 pp pressure vs. the prior year.

We recorded pressures in personnel expenses, stemming from investments into our employee value proposition (EVP) since 4Q25, in last-mile deliveries and in other services. These were almost entirely offset by dilutions in rentals, payment methods and software licenses, in addition to operating leverage resulting from the strong mature-store sales growth above inflation.

GENERAL & ADMINISTRATIVE EXPENSES



General and administrative expenses totaled R$ 308.3 million in 2Q26, corresponding to 2.4% of gross revenue and a 0.3 pp dilution vs. the prior year. We recorded dilutions in personnel expenses, in addition to operating leverage resulting from the strong mature-store sales growth above inflation.

EBITDA



We recorded an adjusted EBITDA of R$ 1,017.3 million in 2Q26 with a stable EBITDA margin of 8.0% of gross revenue. The 17.9% increase vs. the prior year underscores the resilient nature of the Company, despite the challenging macro backdrop.

DEPRECIATION, NET FINANCIAL EXPENSES AND EBT







* Includes the effects of taxation on investment subsidies, in accordance with the Law 14,789/2023.

Adjusted depreciation expenses totaled R$ 277.1 million in 2Q26, equivalent to 2.2% of gross revenue, a dilution of 0.1 pp.

Adjusted net financial expenses totaled R$ 197.3 million in 2Q26, representing 1.5% of gross revenue, a dilution of 0.4 pp vs. the prior year. Of the total amount, R$ 131.8 million refer to the net financial interest accrued on financial liabilities, equivalent to 1.0% of gross revenue with a 0.3 pp reduction, driven by a lower average Selic rate and by R$ 15.8 million in financial revenue from the sale of 4Bio. Additionally, R$ 65.5 million refer to the non-cash NPV adjustment, equivalent to 0.5% of gross revenue with a 0.1 pp dilution.

Lastly, we recorded an adjusted EBT of R$ 542.7 million in 2Q26, a 33.4% increase vs. the prior year. This was equivalent to a margin of 4.2% of gross revenue with a 0.4 pp expansion.

INCOME TAXES AND NET INCOME



* Includes the effects of taxation on investment subsidies, in accordance with the Law 14,789/2023.
** Effective tax rate.



We provisioned a total of R$ 118.3 million in adjusted income tax in 2Q26, 0.9% of gross revenue, an increase of 0.3 pp vs. the prior year. The effective tax rate for 2Q26 was 21.8% of EBT, an increase of 6.3 pp. This increase was driven by the lower proportion of interest on equity provisioned in the quarter and by the retroactive one-off gain of R$ 11.5 million in the previous year from tax subventions in the state of Goiás. We estimate the recurring effective tax rate for 1H26 to be 19.1% of EBT.

Lastly, the 2Q26 adjusted consolidated net income, which only includes 1 month of 4Bio's discontinued operations, was of R$ 432.7 million, with a net margin of 3.4% of gross revenue. This equates to a 0.3 pp contraction vs. the prior year, which still included 3 months of 4Bio results. Excluding discontinued operations, adjusted net income was of R$ 424.4 million, a 23.4% growth vs. the prior year, with a net margin of 3.3% and a 0.1 pp expansion.

EBITDA & NET INCOME RECONCILIATION AND NON-RECURRING RESULTS

Adjusted EBITDA & Net Income Reconciliation (R$ millions)	**2Q25**	**2Q26**
Net income	**400.9**	**440.0**
Results of discontinued operations (4Bio)	(58.7)	(8.3)
Income tax	62.0	122.0
Equity equivalence	0.5	0.2
Financial result	204.0	195.2
EBIT (ex-4Bio)	**608.6**	**749.1**
Depreciation and amortization	251.5	277.1
EBITDA (ex-4Bio)	**860.2**	**1,026.2**
Asset write-offs	(0.9)	7.0
Social investments and donations	11.2	5.0
Tax effects from previous years	(2.3)	(6.8)
Other non-recurring/non-operating effects	(5.2)	(14.1)
Adjusted EBITDA (ex-4Bio)	**863.0**	**1,017.3**
Net income	**400.9**	**440.0**
Net non-rec. effects of discont. operations (4Bio)	0.0	0.0
Non-recurring EBITDA effects	2.8	(8.9)
Non-recurring financial revenues	-	(2.2)
Non-rec. effects of cont. op. on income taxes (34%)	(1.0)	3.7
Adjusted net income	**402.7**	**432.7**

Within our EBITDA, we recorded R$ 8.9 million in net non-recurring revenues in the 2Q26. This includes expenses of R$ 7.0 million in asset write-offs and R$ 5.0 million in social investments & donations, as well as revenues of R$ 6.8 million in gains related to tax effects of previous years and R$ 14.1 million in other non-recurring effects, primarily related to investees. In net income, we recorded R$ 2.2 million non-recurring financial revenues and R$ 3.7 million in income taxes from the non-recurring effects.

CASH CYCLE



* Adjusted for discounted receivables & advanced payments to suppliers.

We recorded a cash cycle of 51.7 days in 2Q26, a reduction of 10.7 days compared to the same period of last year, adjusted for discounted receivables and advanced payments to suppliers and including the positive effects derived from the end of the ICMS-ST tax regime in the state of São Paulo. This improvement was driven primarily by an increase of 10.9 days in suppliers and a decrease of 1.2 days in inventories, more than offsetting an increase of 1.4 days in receivables.

CASH FLOW

Cash flow (R$ millions)	2Q25 Ex-4Bio	2Q26
Adjusted EBIT	**611.4**	**740.2**
NPV adjustment	(65.5)	(56.6)
Non-recurring effects	(2.8)	11.0
Income tax (34%)	(184.7)	(236.2)
Depreciation	251.3	277.2
Impairment provision (4Bio)	-	6.7
Others	(14.6)	67.5
Resources from operations	**595.2**	**809.9**
Cash cycle*	(333.5)	(71.2)
Other assets (liabilities)**	(6.9)	140.7
Operating cash flow	**254.8**	**879.4**
Investments	(315.6)	(329.4)
Free cash flow	**(60.8)**	**550.0**
Investment activities in investees	(17.9)	227.4
Interest on equity and dividends	(308.3)	(246.3)
Income tax paid over interest on equity	(15.4)	(23.3)
Net financial expenses***	(143.8)	(131.8)
Tax benefit (fin. exp., IoE, dividends)	93.7	97.4
Total cash flow (ex-4Bio)	**(452.6)**	**473.2**
Effects from discontinued operations (4Bio)	95.3	716.4
Total (including 4Bio effects)	**(357.2)**	**1,189.7**

*Includes adjustments to discounted receivables. **Incl. NPV. ***Excl. NPV.

We generated R$ 816.7 million in resources from operations in 2Q26 (6.4% of gross revenue) with an operating cash flow of R$ 877.7 million. We generated R$ 61.1 million in working capital and invested R$ 329.4 million in CAPEX, with R$ 144.3 million allocated to the opening of new pharmacies, R$ 85.3 million to maintenance and renovation of existing units, R$ 74.1 million to technology, R$ 18.1 million to logistics, and R$ 7.8 million to other projects. In investees, we recorded R$ 144.5 million from the incorporated cash position of Stix and of R$ 100.0 million from the first installment for the sale of 4Bio, as well as R$ 716,4 million for the remainder of the deal.

Net financial expenses resulted in a cash outflow of R$ 131.8 million in 2Q26. These expenses were partially offset by a tax deduction of R$ 97.4 million related to financial expenses and interest on equity (IoE). Finally, we announced R$ 154.5 million in IoE and R$ 47.6 million in dividends in 2Q26, compared with R$ 131.8 million in IoE and R$ 104.0 million in dividends in 2Q25.

INDEBTEDNESS

Net debt (R$ millions)	2Q25	3Q25	4Q25	1Q26	2Q26
Short-term debt	849.7	522.5	508.1	425.5	365.3
Long-term debt	2,758.6	2,760.1	3,359.6	3,236.1	3,087.4
Total gross debt	**3,608.3**	**3,282.6**	**3,867.8**	**3,661.5**	**3,452.6**
(-) Cash and equivalents	376.3	339.6	358.6	441.8	536.5
Net debt	**3,232.0**	**2,943.0**	**3,509.1**	**3,219.7**	**2,916.1**
Discounted receivables	761.2	514.7	800.3	953.6	808.9
Advances to suppliers	(13.2)	(3.7)	-	-	(25.7)
Sale of 4Bio - Pending receivables	-	-	-	-	(716.4)
Investment put/call options (estimated)	14.4	22.8	15.5	15.9	16.6
Adjusted net debt	**3,994.4**	**3,476.7**	**4,324.9**	**4,189.2**	**2,999.6**
LTM adjusted EBITDA	2,974.4	3,056.3	3,303.1	3,500.7	3,655.0
Adjusted net debt/LTM EBITDA	**1.3x**	**1.1x**	**1.3x**	**1.2x**	**0.8x**

We ended the 2Q26 with adjusted net debt of R$ 2,999.6 million, corresponding to a financial leverage ratio of 0.8x the adjusted EBITDA for the last 12 months, a 0.5x leverage reduction vs. the prior year. This reduction is comprised of 0.3x from the regular cash generation of operations and 0.2x from the sale of 4Bio.

Our adjusted net debt considers a balance of R$ 808.9 million in discounted receivables, of R$ 25.7 million in forward payments to suppliers, R$ 716.4 million in pending receivables related to the sale of 4Bio and R$ 16.6 million in obligations related to put/call options for remaining equity interests in investee companies.

Gross debt totaled R$ 3,452.6 million, fully comprised by the issuance of Debentures and Real Estate Receivables Certificates (CRIs), all with a reaffirmed AAA.br rating from Moody's. Of total indebtedness, 89% is long-term and 11% is short-term. We ended the quarter with a total cash and equivalents position of R$ 536.5 million.

Despite a low leverage of 0.8x, we highlight that we expect additional cash generation over time from the sale of 4Bio and from the recovery of ICMS-ST taxes from inventories in the state of São Paulo.

TOTAL SHAREHOLDER RETURNS

Stock price appreciation



Our share price decreased 26.1% in 2Q26, while the IBOVESPA decreased by 8.5%. During the period, the average daily trading volume (ADTV) was R$ 220 million.

Since the IPO of Drogasil in June 2007, we achieved a cumulative share appreciation of 2,023%, compared to only 216% for the IBOVESPA. Including the payment of interest on equity and dividends, we generated an average annual total return to shareholders of 18.3%.

Considering the IPO of Raia in December 2010, the cumulative return amounted to 512%, compared to 153% for the IBOVESPA. Including shareholder distributions, this equates to an average annual return of 13.4%.

IFRS-16

Since 2019, the financial statements have been prepared in accordance with IFRS 16. However, for historical comparability purposes, the figures presented in this report exclude the effects of this standard, as we believe the previous accounting approach better reflects the economic reality of our business. On RD Saúde's Investor Relations website (ir.rdsaude.com.br), the financial statements can be found in the 'Results Spreadsheets' section.

Income Statement *(R$ millions)*	2Q26 Pre IFRS 16	2Q26 IFRS 16	Change Δ 2Q26
Gross Revenue	**12,777.7**	**12,777.7**	**0.0**
Gross Profit	**3,696.1**	**3,697.7**	**1.7**
Gross Margin	28.9%	28.9%	0.0 pp
Selling Expenses	(2,370.4)	(2,013.0)	357.4
G&A	(308.3)	(307.6)	0.7
Total Expenses	**(2,678.7)**	**(2,320.6)**	**358.1**
as % of Gross Revenue	21.0%	18.2%	(2.8 pp)
Adjusted EBITDA	**1,017.3**	**1,377.1**	**359.8**
as % of Gross Revenue	8.0%	10.8%	2.8 pp
Non-Recurring Expenses / Revenues	8.9	9.6	0.8
Depreciation and Amortization	(277.1)	(532.5)	(255.4)
Financial Results	(195.2)	(323.7)	(128.5)
Income Tax	(122.0)	(114.1)	8.0
Net income ex-4Bio	**431.7**	**416.3**	**(15.4)**
as % of Gross Revenue	3.4%	3.3%	(0.1 pp)
Net Income	**440.0**	**424.5**	**(15.4)**
as % of Gross Revenue	3.4%	3.3%	(0.1 pp)

Balance Sheet *(R$ millions)*	2Q26 Pre IFRS 16	2Q26 IFRS 16	Change Δ 2Q26
Assets	**20,154.5**	**24,822.6**	**4,668.1**
Current Assets	**14,251.7**	**14,251.7**	**(0.0)**
Non-Current Assets	**5,902.7**	**10,570.9**	**4,668.1**
Income Tax and Social Charges deferred	51.0	255.7	204.7
Other Credits	541.6	541.1	(0.4)
Investments	0.2	0.0	(0.2)
Right of use	0.0	4,464.1	4,464.1
Liabilities and Shareholder's Equity	**20,154.5**	**24,822.6**	**4,668.1**
Current Liabilities	**9,116.2**	**10,135.7**	**1,019.6**
Financial Leases	0.0	1,025.3	1,025.3
Other Accounts Payable	593.7	588.0	(5.7)
Non-Current Liabilities	**3,304.4**	**7,396.1**	**4,091.7**
Financial Leases	0.0	4,115.1	4,115.1
Income Tax and Social Charges Deferred	23.4	0.0	(23.4)
Shareholder's Equity	**7,733.9**	**7,290.8**	**(443.1)**
Income Reserves	2,489.1	2,075.7	(413.4)
Accrued Income	261.0	231.4	(29.7)
Equity Adjustments	63.0	63.0	(0.1)

Cash Flow *(R$ millions)*	2Q26 Pre IFRS 16	2Q26 IFRS 16	Change Δ 2Q26
Adjusted EBIT	**740.2**	**844.6**	**104.4**
Non-Recurring Effects	11.0	9.6	(1.4)
Income Tax (34%)	(236.2)	(271.2)	(35.0)
Depreciation	277.2	532.5	255.3
Rental Expenses	0.0	(358.9)	(358.9)
Others	67.5	109.8	42.3
Resources from Operations	**809.9**	**816.6**	**6.7**
Operating Cash Flow	**879.4**	**879.4**	**0.0**
Investments	**(329.4)**	**(329.4)**	**0.0**
Free Cash Flow	**550.0**	**550.0**	**0.0**
Total cash flow (ex-4Bio)	**473.2**	**473.2**	**0.0**
Total cash flow (with 4Bio)	**1,189.7**	**1,189.7**	**0.0**

RESULTS CONFERENCE CALL

August 05th 2026, 10:00 AM (BRT),
with simultaneous translation to English.

Access link
https://www.resultadosrdsaude.com.br/

For more information, please contact our Investor Relations department: ri@rdsaude.com.br

Consolidated adjusted income statement	2Q25	2Q26
(R$ thousands)	Resubmitted	
Gross revenue	**10,803,986**	**12,777,743**
Taxes, deductions and returns	(729,303)	(1,715,344)
Net revenue	**10,074,683**	**11,062,399**
Cost of goods sold	(6,940,850)	(7,366,328)
Gross profit	**3,133,833**	**3,696,071**
Selling expenses	(1,982,851)	(2,370,424)
General and administrative expenses	(288,002)	(308,299)
Operational expenses	**(2,270,853)**	**(2,678,723)**
Adjusted EBITDA	**862,980**	**1,017,348**
Depreciation and amortization	(251,535)	(277,134)
Operational earnings before financial results	**611,445**	**740,214**
Financial expenses	(310,428)	(336,869)
Financial revenue	106,401	139,545
Financial results	**(204,027)**	**(197,324)**
Equity equivalence	(467)	(180)
Earnings before income tax and social charges	**406,951**	**542,709**
Income tax and social charges	(62,941)	(118,284)
Adjusted net income ex-4Bio	**344,011**	**424,425**
Results of discontinued operations (4Bio)	58,734	8,304
Adjusted net income	**402,744**	**432,729**

Consolidated income statement (R$ thousands)	2Q25 Resubmitted	2Q26
Gross revenue	**10,803,986**	**12,777,743**
Taxes, deductions and returns	(729,303)	(1,715,344)
Net revenue	**10,074,683**	**11,062,399**
Cost of goods sold	(6,940,850)	(7,366,328)
Gross profit	**3,133,833**	**3,696,071**
Selling expenses	(1,982,851)	(2,370,424)
General and administrative expenses	(288,002)	(308,299)
Other operational expenses, net	(2,796)	8,850
Operational expenses	**(2,273,649)**	**(2,669,873)**
EBITDA	**860,184**	**1,026,198**
Depreciation and amortization	(251,535)	(277,134)
Operational earnings before financial results	**608,649**	**749,064**
Financial expenses	(310,428)	(336,869)
Financial revenue	106,401	141,705
Financial results	**(204,027)**	**(195,165)**
Equity equivalence	(467)	(180)
Earnings before income tax and social charges	**404,156**	**553,719**
Income tax and social charges	(61,990)	(122,028)
Net income ex-4Bio	**342,166**	**431,691**
Results of discontinued operations (4Bio)	58,689	8,287
Net income	**400,855**	**439,978**

Assets (R$ thousands)	2Q25	2Q26
Cash and cash equivalents	376,334	536,500
Financial investments	78,278	116,449
Accounts receivable	2,373,076	3,095,748
Inventories	7,948,264	8,333,897
Taxes receivable	436,987	1,066,713
Anticipated expenses	151,808	156,290
Judicial deposits	4,060	3,782
Assets of investment for sale (4Bio)	1,658,025	-
Other accounts receivable	609,794	942,368
Current assets	13,636,626	14,251,747
Deposit in court	32,718	64,898
Taxes receivable	225,666	236,634
Income tax and social charges deferred	48,182	51,012
Other credits	14,928	541,551
Investments	13,447	186
Property, plant and equipment	2,737,578	2,970,046
Intangible	2,036,972	2,038,393
Non-current assets	5,109,491	5,902,720
TOTAL ASSETS	**18,746,118**	**20,154,467**

Liabilities and shareholder equity (R$ thousands)	2Q25	2Q26
Suppliers	5,192,141	6,375,302
Loans and financing	849,691	365,266
Salaries and social charges payable	777,866	925,554
Taxes payable	384,088	508,068
Dividends and interest on equity	217,181	306,115
Provision for lawsuits	77,279	42,116
Liabilities of investment for sale (4Bio)	796,567	-
Other accounts payable	415,224	593,734
Current liabilities	8,710,038	9,116,156
Loans and financing	2,758,638	3,087,383
Provision for lawsuits	102,133	145,181
Income tax and social charges deferred	25,503	23,417
Other accounts payable	77,625	48,458
Non-current liabilities	2,963,899	3,304,440
Common stock	4,000,000	4,750,000
Capital reserves	131,107	159,823
Revaluation reserve	11,022	10,895
Income reserves	2,529,320	2,489,084
Accrued income	322,824	261,046
Equity adjustments	62,969	63,023
Non controller interest	14,939	-
Shareholder equity	7,072,180	7,733,871
TOTAL LIABILITIES & SHAREHOLDER EQUITY	**18,746,118**	**20,154,467**

Cash Flow (with 4Bio)	2Q25	2Q26
(R$ thousands)		
Earnings before Income Tax and Social Charges	**427,170**	**553,718**
Adjustments		
Depreciation and Amortization	252,432	277,204
Compensation plan with restricted shares, net	13,213	10,819
Interest over additional stock option	467	723
PP&E and Intangible Assets residual value	1,016	54,020
Provisioned Lawsuits	(10,330)	20,579
Provisioned Inventory Loss	(19,142)	(5,535)
Provision for Doubtful Accounts	9,063	2,709
Provisioned Store Closures	(310)	4,492
Interest Expenses	125,090	125,301
Debt Issuance Costs Amortization	2,444	1,917
Equity Equivalence Result	434	180
Gains from business combination	-	(19,568)
Provision for realization of recoverable investment	-	6,698
	801,547	**1,033,257**
Assets and Liabilities variation		
Clients and Other Accounts Receivable	(208,850)	(263,318)
Inventories	296,920	112,545
Other Short Term Assets	(116,409)	(144,793)
Suppliers	(403,675)	(90,789)
Salaries and Social Charges	133,527	177,082
Taxes Payable	(13,557)	52,356
Other Liabilities	(99,620)	(84,754)
Rents Payable	6,032	27,094
Cash from Operations	**395,915**	**818,679**
Interest Paid	(94,936)	(186,025)
Income Tax and Social Charges Paid	(26,165)	-
Paid lawsuits	(8,020)	(33,918)
Net Cash from (invested) Operational Activities	**266,794**	**598,736**
Investment Activities Cash Flow		
Cash acquired from business combination	-	144,517
PP&E and Intangible Acquisitions	(323,410)	(324,281)
PP&E Sale Payments	-	533
Restricted Investments	(12,484)	(20,515)
Acquisitions and capital contributions in investments, net	-	(2,300)
Cash from divestments	-	100,000
Net Cash from Investment Activities	**(335,894)**	**(102,046)**
Financing Activities Cash Flow		
Funding	500,000	-
Payments	-	(150,000)
Interest on Equity and Dividends Paid	(308,261)	(246,301)
Senior Quota Redemptions	-	(5,691)
Net Cash from Funding Activities	**191,739**	**(401,992)**
Cash and equivalents in the beggining of the period (with 4Bio)	**404,381**	**441,801**
Cash and equivalents net increase (with 4Bio)	122,639	94,698
Cash and equivalents in the end of the period (with 4Bio)	**527,020**	**536,500**

Balance sheets
June 30, 2026
All amounts in thousands of reais

Assets	Note	Parent Company Jun/26	Parent Company Dec/25	Consolidated Jun/26	Consolidated Dec/25
Current assets					
Cash and cash equivalents	5	322,902	296,965	536,501	509,619
Financial investments	6	28,624	28,112	116,449	19,120
Trade receivables	7	2,977,266	2,757,988	3,095,749	3,400,585
Inventories	8	8,328,343	9,127,427	8,333,896	9,576,343
Recoverable taxes	9	1,054,574	509,584	1,066,713	541,373
Other current assets	-	865,112	585,693	942,364	647,316
Prepaid expenses	-	147,436	112,816	156,289	116,027
Related parties	27	98,182	96,371	-	89,095
Judicial deposits	18	3,782	4,970	3,782	4,970
		13,826,221	**13,519,926**	**14,251,743**	**14,904,448**
Non-current assets					
Long-term receivables					
Judicial deposits	18	64,862	61,226	64,898	296,349
Recoverable taxes	9	236,634	227,331	236,634	255,077
Deferred income tax and social contribution	19.2	204,655	204,880	255,666	357,487
Prepaid expenses	-	5,000	6,824	5,000	6,824
Other non-current assets	-	535,841	156	536,120	336
		1,046,992	**500,417**	**1,098,318**	**916,073**
Investments	10	473,026	1,390,158	-	19,463
Property, plant and equipment	11	2,929,453	2,891,356	2,970,046	2,942,880
Intangible assets	12	1,743,360	1,762,278	2,038,393	2,051,563
Right-of-use assets	17	4,462,940	4,329,246	4,464,098	4,336,048
		9,608,779	**10,373,038**	**9,472,537**	**9,349,954**
		10,655,771	**10,873,455**	**10,570,855**	**10,266,027**
Total assets		**24,481,992**	**24,393,381**	**24,822,598**	**25,170,475**

Liabilities and equity	Note	Parent Company Jun/26	Parent Company Dec/25	Consolidated Jun/26	Consolidated Dec/25
Current liabilities					
Suppliers	14	6,250,944	6,425,749	6,120,777	6,680,650
Liabilities with senior quotaholders in FIDC	15	-	-	243,938	228,549
Borrowings	16	365,266	508,137	365,266	508,137
Leases payable	17	1,025,101	1,019,344	1,025,313	1,021,147
Salaries and social charges	-	879,572	737,699	925,555	772,590
Taxes and contributions	-	431,046	351,343	437,146	373,913
Dividends and interest on capital	-	306,115	2,566	306,115	2,566
Income tax and social contribution	-	65,454	35,632	70,923	43,262
Provision for legal claims	18	42,116	58,220	42,116	58,220
Related parties	27	20,519	22,366	-	22,366
Other current liabilities	-	430,943	428,137	598,575	482,500
		9,817,076	**9,589,193**	**10,135,724**	**10,193,900**
Non-current liabilities					
Borrowings	16	3,087,383	3,359,618	3,087,383	3,359,618
Leases payable	17	4,114,073	3,939,887	4,115,073	3,945,165
Provision for legal claims	18	145,181	135,298	145,181	248,853
Payables for acquisition of subsidiaries	-	16,578	15,518	16,578	15,518
Provisions for losses on investments	10	-	-	1,255	-
Other non-current liabilities	-	10,921	31,738	30,624	71,453
		7,374,136	**7,482,059**	**7,396,094**	**7,640,607**
Total liabilities		**17,191,212**	**17,071,252**	**17,531,818**	**17,834,507**
Equity	21				
Attributable to owners of the Company					
Share capital	-	4,750,000	4,750,000	4,750,000	4,750,000
Capital reserves	-	159,823	139,291	159,823	139,291
Revenue reserves	-	2,075,725	2,075,725	2,075,725	2,075,725
Proposed additional dividend	-	-	283,184	-	283,184
Carrying value adjustments	-	73,864	73,929	73,864	73,929
Retained earnings	-	231,368	-	231,368	-
		7,290,780	**7,322,129**	**7,290,780**	**7,322,129**
Noncontrolling interests	-	-	-	-	13,839
Total equity		**7,290,780**	**7,322,129**	**7,290,780**	**7,335,968**
Total liabilities and equity		**24,481,992**	**24,393,381**	**24,822,598**	**25,170,475**

All amounts in thousands of reais, except earnings per capital share

Statements of income

		Parent Company				Consolidated			
	Note	2nd Quarter/26	Jun/26	2nd Quarter/25	Jun/25	2nd Quarter/26	Jun/26	2nd Quarter/25 Restated	Jun/25 Restated
Net sales revenue	21	11,000,092	21,522,568	10,024,530	19,255,545	11,062,398	21,630,988	10,074,623	19,347,587
Cost of sales and services	22	(7,336,087)	(14,487,494)	(6,913,592)	(13,341,811)	(7,364,668)	(14,538,958)	(6,938,580)	(13,389,496)
Gross profit		**3,664,005**	**7,035,074**	**3,110,938**	**5,913,734**	**3,697,730**	**7,092,030**	**3,136,043**	**5,958,091**
Operating (expenses) income									
Selling	22	(2,459,651)	(4,823,267)	(2,069,737)	(4,063,312)	(2,465,559)	(4,835,060)	(2,075,835)	(4,075,127)
General and administrative	22	(368,411)	(725,687)	(342,674)	(693,008)	(387,571)	(763,238)	(361,903)	(730,082)
Other operating income/(expenses)	23	9,226	(186,186)	(6,896)	(10,987)	9,618	(185,808)	(1,719)	(6,953)
Equity in the results of subsidiaries	10	13,448	24,898	62,473	77,200	(179)	(417)	(434)	(1,708)
		(2,805,388)	**(5,710,242)**	**(2,356,834)**	**(4,690,107)**	**(2,843,691)**	**(5,784,523)**	**(2,439,891)**	**(4,813,870)**
Operating profit before finance results		**858,617**	**1,324,832**	**754,104**	**1,223,627**	**854,039**	**1,307,507**	**696,152**	**1,144,221**
Finance income (costs)									
Finance income	24	139,709	283,372	95,606	180,370	141,705	288,100	106,402	192,574
Finance costs	24	(464,499)	(937,526)	(425,420)	(794,021)	(465,406)	(938,470)	(425,655)	(794,425)
		(324,790)	**(654,154)**	**(329,814)**	**(613,651)**	**(323,701)**	**(650,370)**	**(319,253)**	**(601,851)**
Profit before income tax and social contribution		**533,827**	**670,678**	**424,290**	**609,976**	**530,338**	**657,137**	**376,899**	**542,370**
Income tax and social contribution									
Current	-	(70,073)	(86,927)	(72,314)	(104,379)	(73,541)	(91,663)	(74,747)	(108,305)
Deferred	-	(39,214)	(256)	22,028	32,374	(40,534)	(1,940)	22,075	32,470
	18	**(109,287)**	**(87,183)**	**(50,286)**	**(72,005)**	**(114,075)**	**(93,603)**	**(52,672)**	**(75,835)**
Profit before discontinued operations		**424,540**	**583,495**	**374,004**	**537,971**	**416,263**	**563,534**	**324,227**	**466,535**
Profit from discontinued operations		**-**	**-**	**-**	**-**	**8,277**	**19,961**	**58,718**	**81,488**
Profit for the period		**424,540**	**583,495**	**374,004**	**537,971**	**424,540**	**583,495**	**382,945**	**548,023**
Attributable to:									
Owners of the Company	-	424,540	583,495	374,004	537,971	424,540	583,495	374,004	537,971
Noncontrolling interests	-	-	-	-	-	-	-	8,941	10,052
		424,540	**583,495**	**374,004**	**537,971**	**424,540**	**583,495**	**382,945**	**548,023**
Net basic earnings per share	19	0.25767	0.35415	0.22711	0.32668	0.25767	0.35415	0.22711	0.32668
Net diluted earnings per share	19	0.25334	0.34820	0.22591	0.32495	0.25334	0.34820	0.22591	0.32495

Voltar

All amounts in thousands of reais, except earnings per capital share

Statements of comprehensive income

		Parent Company				Consolidated			
	Note	2nd Quarter/26	Jun/26	2nd Quarter/25	Jun/25	2nd Quarter/26	Jun/26	2nd Quarter/25 Restated	Jun/25 Restated
Profit for the period		**424,540**	**583,495**	**374,004**	**537,971**	**424,540**	**583,495**	**382,945**	**548,023**
Components of comprehensive income	-								
Other comprehensive income that will affect the result in a subsequent period	-	-	-	-	-	-	-	-	-
Total comprehensive income for the period		**424,540**	**583,495**	**374,004**	**537,971**	**424,540**	**583,495**	**382,945**	**548,023**
Attributable to:									
Owners of the Company	-	424,540	583,495	374,004	537,971	424,540	583,495	374,004	537,971
Noncontrolling interests	-	-	-	-	-	-	-	8,941	10,052
Total		**424,540**	**583,495**	**374,004**	**537,971**	**424,540**	**583,495**	**382,945**	**548,023**

Voltar

Statements of changes in equity
Six-month period ended June 30, 2026
All amounts in thousands of reais

	Attributable to owners of the Company															
		Capital reserves				Revenue reserves					Carrying value adjustments					
	Share capital	Special monetary adjustment	Goodwill on issue / sale of shares	Treasury shares	Restricted shares and other	Legal	Statutory	Tax incentives	Retained earnings	Proposed additional dividend	Revaluation reserve	Transactions with noncontrolling interests	Other comprehensive income	Total	Noncontrolling interests	Total equity
At December 31, 2024	**4,000,000**	**10,191**	**135,872**	**(124,991)**	**90,237**	**378,498**	**983,106**	**816,597**	**-**	**69,895**	**11,087**	**3,262**	**59,706**	**6,433,460**	**13,427**	**6,446,887**
Realization of revaluation reserve, net of income tax and social contribution	-	-	-	-	-	-	-	-	64	-	(64)	-	-	**-**	-	**-**
Interest on capital expired	-	-	-	-	-	-	-	-	399	-	-	-	-	**399**	-	**399**
Interest on capital for 2024 approved at the AGEM of April 22, 2025	-	-	-	-	-	-	-	-	-	(69,895)	-	-	-	**(69,895)**	-	**(69,895)**
Restricted share plan - vesting period	-	-	-	-	19,644	-	-	-	-	-	-	-	-	**19,644**	-	**19,644**
Restricted share plan - delivery	-	-	7,606	19,863	(27,896)	-	-	-	-	-	-	-	-	**(427)**	-	**(427)**
Restricted shares – delivery of restricted shares	-	-	-	1,100	(519)	-	-	-	-	-	-	-	-	**581**	-	**581**
Acquisition of shares from noncontrolling interests through exercise of call option – 4Bio	-	-	-	-	-	-	-	-	-	-	-	-	-	**-**	(8,738)	**(8,738)**
Profit for the period	-	-	-	-	-	-	-	-	537,971	-	-	-	-	**537,971**	10,052	**548,023**
Interest on capital proposed	-	-	-	-	-	-	-	-	(249,900)	-	-	-	-	**(249,900)**	-	**(249,900)**
At June 30, 2025	**4,000,000**	**10,191**	**143,478**	**(104,028)**	**81,466**	**378,498**	**983,106**	**816,597**	**288,534**	**-**	**11,023**	**3,262**	**59,706**	**6,671,833**	**14,741**	**6,686,574**
Capital Increase approved at the Board of Directors' Meeting on December 22, 2025	750,000	-	-	-	-	-	(750,000)	-	-	-	-	-	-	**-**	-	**-**
Interest on capital expired	-	-	-	-	-	-	-	-	339	-	-	-	-	**339**	-	**339**
Realization of revaluation reserve, net of income tax and social contribution	-	-	-	-	-	-	-	-	62	-	(62)	-	-	**-**	-	**-**
Restricted share plan - vesting period	-	-	-	-	8,236	-	-	-	15,799	-	-	-	-	**24,035**	-	**24,035**
Restricted share plan - delivery	-	-	-	(53)	-	-	-	-	-	-	-	-	-	**(53)**	-	**(53)**
Restricted shares – delivery of restricted shares	-	-	-	(1)	2	-	-	-	-	-	-	-	-	**1**	-	**1**
Acquisition of shares from noncontrolling interests through exercise of call option – 4Bio	-	-	-	-	-	-	-	-	-	-	-	-	-	**-**	5,768	**5,768**
Profit for the period	-	-	-	-	-	-	-	-	758,890	-	-	-	-	**758,890**	(6,670)	**752,220**
Interest on capital proposed	-	-	-	-	-	-	-	-	(286,100)	536,000	-	-	-	**249,900**	-	**249,900**
Legal reserve	-	-	-	-	-	64,842	-	-	(64,842)	-	-	-	-	**-**	-	-
Proposed dividends - R$ 0.075890 per share (Note 21)	-	-	-	-	-	-	-	-	(130,000)	130,000	-	-	-	**-**	-	-
Statutory reserve	-	-	-	-	-	-	582,682	-	(582,682)	-	-	-	-	**-**	-	-
Withholding tax on IOC (Note 21)	-	-	-	-	-	-	-	-	-	(74,780)	-	-	-	**(74,780)**	-	**(74,780)**
Reclassification of minimum mandatory dividends to current liabilities	-	-	-	-	-	-	-	-	-	(308,036)	-	-	-	**(308,036)**	-	**(308,036)**
At December 31, 2025	**4,750,000**	**10,191**	**143,478**	**(104,082)**	**89,704**	**443,340**	**815,788**	**816,597**	**-**	**283,184**	**10,961**	**3,262**	**59,706**	**7,322,129**	**13,839**	**7,335,968**
Realization of revaluation reserve, net of income tax and social contribution	-	-	-	-	-	-	-	-	65	-	(65)	-	-	**-**	-	**-**
Interest on capital expired	-	-	-	-	-	-	-	-	307	-	-	-	-	**307**	-	**307**
Restricted share plan - vesting period	-	-	-	-	17,010	-	-	-	-	-	-	-	-	**17,010**	-	**17,010**
Restricted share plan - delivery	-	-	4,391	24,316	(30,094)	-	-	-	-	-	-	-	-	**(1,387)**	-	**(1,387)**
Restricted shares – delivery of restricted shares	-	-	-	1,387	3,522	-	-	-	-	-	-	-	-	**4,909**	-	**4,909**
Acquisition of shares from noncontrolling interests through exercise of call option – 4Bio	-	-	-	-	-	-	-	-	-	-	-	-	-	**-**	(13,839)	**(13,839)**
Profit for the period	-	-	-	-	-	-	-	-	583,496	-	-	-	-	**583,496**	-	**583,496**
Interest on capital proposed	-	-	-	-	-	-	-	-	(304,900)	-	-	-	-	**(304,900)**	-	**(304,900)**
Dividends for the period	-	-	-	-	-	-	-	-	(47,600)	-	-	-	-	**(47,600)**	-	**(47,600)**
Reclassification of minimum mandatory dividends to current liabilities	-	-	-	-	-	-	-	-	-	(283,184)	-	-	-	**(283,184)**	-	**(283,184)**
At June 30, 2026	**4,750,000**	**10,191**	**147,869**	**(78,379)**	**80,142**	**443,340**	**815,788**	**816,597**	**231,368**	**-**	**10,896**	**3,262**	**59,706**	**7,290,780**	**-**	**7,290,780**

All amounts in thousands of reais

	Note	Parent Company Jun/26	Parent Company Jun/25	Consolidated Jun/26	Consolidated Jun/25 Restated
Cash flows from operating activities					
Profit before income tax and social contribution	-	**670,678**	**609,976**	**657,137**	**542,370**
Adjustments					
Depreciation and amortization	23	1,082,510	993,265	1,090,825	1,001,460
Compensation plan with restricted shares, net	-	20,532	19,798	20,532	19,798
Interest on additional stock option	-	1,060	872	1,060	872
Profit on sale/write-off of fixed assets and intangible assets	-	3,602	5,342	54,988	5,342
Provision for (reversal of) legal claims	18	47,193	28,520	47,193	12,178
(Reversal of) provision for inventory losses	8	(9,876)	(6,707)	(9,876)	(6,707)
(Reversal of) provision for impairment of trade receivables	7	5,848	6,347	5,679	7,408
(Reversal of) provision for pharmacies closure	11 and 12	4,345	(2,918)	4,345	(2,918)
Expenses net of interest on borrowings	16	261,143	227,083	261,143	228,067
Amortization of transaction costs of debentures	16	4,133	4,828	4,133	4,828
Equity in the results of subsidiaries	10	(24,898)	(77,200)	417	1,708
Interest expenses – leases	17	268,275	231,691	268,582	232,000
Discontinued operation		-	-	-	57,954
Gain on business combination		(19,568)	-	(19,568)	-
Provision for impairment of investment	30	202,796	-	202,796	-
		2,517,773	**2,040,897**	**2,589,386**	**2,104,360**
Changes in assets and liabilities					
Trade and other receivables	-	(225,126)	(399,482)	(357,774)	(367,346)
Inventories	-	808,960	36,638	836,425	91,172
Other assets	-	(182,180)	(208,595)	(495,355)	(259,307)
Suppliers	-	(169,034)	(162,827)	(5,158)	(155,433)
Salaries and social charges	-	141,873	104,233	170,514	106,895
Taxes and contributions	-	(444,768)	94,504	(474,386)	72,718
Other obligations	-	(181,663)	(136,229)	(48,228)	(108,724)
Rentals payable	-	26,008	6,480	26,008	6,545
Other					
Interest paid	16	(280,729)	(195,702)	(280,729)	(197,858)
Income tax and social contribution paid	-	(30,354)	(26,165)	(30,354)	(26,165)
Interest paid – leases	17	(268,275)	(231,691)	(268,582)	(232,000)
Legal claims – paid	18	(53,414)	(17,617)	(53,414)	(17,617)
Net cash provided by operating activities		**1,659,071**	**904,444**	**1,608,353**	**1,017,240**
Cash flows from investing activities					
Acquisition and capital contribution in investees	-	(14,520)	(92,670)	(2,300)	-
Cash acquired in business combination	10.1	-	-	144,517	-
Purchases of fixed assets and intangible assets	11 and 12	(578,099)	(582,512)	(584,233)	(593,938)
Proceeds from sale of fixed assets		533	-	533	-
Financial investments		-	-	(97,329)	(62,573)
Proceeds from disposal of investee		100,000	-	100,000	-
Net cash used in investing activities		**(492,086)**	**(675,182)**	**(438,812)**	**(656,511)**
Cash flows from financing activities					
Borrowings taken	16	-	500,000	-	590,000
Repayment of borrowings	16	(400,000)	(125,000)	(400,000)	(213,869)
Leases paid	-	(494,256)	(428,352)	(490,176)	(429,479)
Interest on capital and dividends paid	-	(246,792)	(308,363)	(246,792)	(308,363)
Redemptions – Senior quotaholders FIDC		-	-	(5,691)	-
Net cash used in financing activities		**(1,141,048)**	**(361,715)**	**(1,142,659)**	**(361,711)**
Increase (decrease) in cash and cash equivalents		25,937	(132,453)	26,882	(982)
Cash and cash equivalents at January 1	5	**296,965**	**460,292**	**509,619**	**528,002**
Cash and cash equivalents at June 30	5	**322,902**	**327,839**	**536,501**	**527,020**

The accompanying notes are an integral part of this interim financial information.

Statements of value added
Six-month period ended June 30, 2026
All amounts in thousands of reais

	Parent Company				Consolidated			
	2nd Quarter/26	Jun/26	2nd Quarter/25	Jun/25	2nd Quarter/26	Jun/26	2nd Quarter/25 Restated	Jun/25 Restated
Revenue	**12,510,312**	**24,251,737**	**10,597,755**	**20,320,394**	**12,576,285**	**24,366,867**	**11,191,084**	**20,954,712**
Gross sales and services	12,507,230	24,246,137	10,596,027	20,362,534	12,573,206	24,361,251	11,191,355	20,998,851
Other income	3,686	6,381	3,484	6,530	3,683	6,397	3,208	6,254
Provision for (reversal of) impairment of trade receivables	(604)	(781)	(1,756)	(48,670)	(604)	(781)	(3,479)	(50,393)
Inputs acquired from third parties	**(8,487,960)**	**(16,647,577)**	**(7,063,888)**	**(13,578,053)**	**(8,516,372)**	**(16,699,805)**	**(7,568,007)**	**(14,107,512)**
Cost of sales and services	(7,631,218)	(14,785,861)	(6,365,962)	(12,256,279)	(7,658,204)	(14,833,870)	(6,846,872)	(12,757,908)
Materials, energy, outsourced services and other	(849,987)	(1,658,920)	(697,926)	(1,321,774)	(851,413)	(1,663,139)	(721,135)	(1,349,604)
(Loss) and recovery of asset values (Note 30)	(6,755)	(202,796)	-	-	(6,755)	(202,796)	-	-
Gross value added	**4,022,352**	**7,604,160**	**3,533,867**	**6,742,341**	**4,059,913**	**7,667,062**	**3,623,077**	**6,847,200**
Depreciation and amortization	(528,697)	(1,049,704)	(486,098)	(965,936)	(532,515)	(1,057,284)	(488,808)	(971,294)
Net value added generated by the entity	**3,493,655**	**6,554,456**	**3,047,769**	**5,776,405**	**3,527,398**	**6,609,778**	**3,134,269**	**5,875,906**
Value added received through transfer	**160,713**	**323,651**	**164,086**	**268,730**	**148,898**	**302,141**	**136,269**	**225,909**
Equity in the results of subsidiaries	13,448	24,898	62,473	77,200	(179)	(417)	(434)	(1,708)
Finance income	140,743	285,229	95,736	180,828	142,555	289,034	130,827	216,915
Other	6,522	13,524	5,877	10,702	6,522	13,524	5,876	10,702
Total value added to distribute - Continuing operations	**3,654,368**	**6,878,107**	**3,211,855**	**6,045,135**	**3,676,296**	**6,911,919**	**3,270,538**	**6,101,815**
Total value added to distribute - Discontinued operations	-	-	-	-	52,967	177,773	45,468	190,849
Total value added to distribute	**3,654,368**	**6,878,107**	**3,211,855**	**6,045,135**	**3,729,263**	**7,089,692**	**3,316,006**	**6,292,664**
Total distribution of value added	**3,654,368**	**6,878,107**	**3,211,855**	**6,045,135**	**3,729,263**	**7,089,692**	**3,316,006**	**6,292,664**
Total distribution of value added – Discontinued operations	-	-	-	-	52,967	177,773	45,468	190,849
Value added distributed and retained – Continuing operations	**3,654,368**	**6,878,107**	**3,211,855**	**6,045,135**	**3,676,296**	**6,911,919**	**3,270,538**	**6,101,815**
Personnel	**1,189,268**	**2,343,064**	**1,020,822**	**2,011,469**	**1,201,770**	**2,367,625**	**1,097,551**	**2,098,400**
Direct remuneration	925,459	1,808,167	798,295	1,586,430	934,766	1,826,570	866,502	1,662,779
Benefits	184,467	376,796	154,291	290,042	186,899	381,550	161,547	298,822
Unemployment compensation fund	79,342	158,101	68,236	134,997	80,105	159,505	69,502	136,799
Taxes and contributions	**1,499,119**	**2,863,526**	**1,313,317**	**2,549,248**	**1,515,930**	**2,891,595**	**1,331,374**	**2,576,471**
Federal	363,949	616,376	266,044	523,830	377,216	637,071	238,922	504,042
State	1,118,553	2,214,634	1,033,409	1,997,933	1,120,181	2,217,666	1,076,737	2,041,446
Municipal	16,617	32,516	13,864	27,485	18,533	36,858	15,715	30,983
Providers of capital	**541,441**	**1,088,022**	**503,712**	**946,447**	**542,333**	**1,089,165**	**517,386**	**960,409**
Interest	464,166	936,749	424,704	793,213	464,883	937,524	437,333	805,877
Rentals	77,275	151,273	79,008	153,234	77,450	151,641	80,053	154,532
Interest on capital and dividends	**424,540**	**583,495**	**374,004**	**537,971**	**416,263**	**563,534**	**324,227**	**466,535**
Interest on capital	154,500	304,900	131,800	249,900	154,500	304,900	79,477	197,577
Retained earnings for the period	270,040	278,595	242,204	288,071	261,763	258,634	235,809	258,906
Noncontrolling interests in retained earnings	-	-	-	-	-	-	8,941	10,052

The accompanying notes are an integral part of this interim financial information.

(All amounts in thousands of reais unless otherwise stated)

1. Operations

Raia Drogasil S.A. ("Company" or "RD Saúde" or "Parent Company") is a publicly-held company with its headquarters at Av. Corifeu de Azevedo Marques, 3.097, São Paulo – SP, listed on the Novo Mercado ("New Market" listing segment of B3 S.A. - Brasil, Bolsa, Balcão, under ticker RADL3. RD Saúde was created in November 2011 from the merger between Droga Raia and Drogasil chains that, together, combine more than 200 years of history. Droga Raia was founded in 1905 and Drogasil in 1935 and today form the leading chain, both in number of pharmacies and in revenues.

On March 18, 2024, the Company changed its brand to "RD Saúde", reflecting its goal to lead health promotion in Brazil. In addition to the pharmaceutical retail segment, RD Saúde focuses on comprehensive health, seeking the well-being of the community and offering high-quality services and products.

RD Saúde and its subsidiaries (together "Group" or "Consolidated") are mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines. The Group conducts its sales through 3,687 pharmacies (3,547 pharmacies – Dec/25), present in all 26 Brazilian states and the Federal District (26 states and the Federal District – Dec/25), as presented below:

	Consolidated	
State	**Jun/26**	**Dec/25**
Southeast region	**2,078**	**2,004**
São Paulo	1,455	1,415
Rio de Janeiro	284	263
Minas Gerais	259	249
Espírito Santo	80	77
Northeast region	**567**	**542**
Bahia	143	126
Pernambuco	121	117
Ceará	113	108
Maranhão	44	44
Sergipe	34	34
Rio Grande do Norte	32	33
Paraíba	30	30
Alagoas	26	26
Piauí	24	24
South region	**467**	**450**
Paraná	211	201
Rio Grande do Sul	140	137
Santa Catarina	116	112
Midwest region	**417**	**396**
Goiás	163	155
Federal District	127	117
Mato Grosso do Sul	70	68
Mato Grosso	57	56
North region	**158**	**155**
Pará	61	59
Amazonas	31	30
Tocantins	29	29
Rondônia	20	20
Acre	7	7
Amapá	5	5
Roraima	5	5
Total	**3,687**	**3,547**

During the current period, 144 pharmacies were opened and 4 pharmacies were closed (until the second quarter of 2025, 145 pharmacies were opened and 4 were closed). All pharmacies closures were carried out to optimize our pharmacies portfolio, with positive expectations of return. RD Saúde's pharmacies, as well as the Group's e-commerce demands, are supplied by sixteen distribution centers located in thirteen states: São Paulo, Rio de Janeiro, Minas Gerais, Espirito Santo, Paraná, Goiás, Pernambuco, Bahia, Ceará, Rio Grande do Sul, Mato Grosso, Amazonas and Pará.

RD Ventures Fundo de Investimento em Participações – Multiestratégia ("FIP RD Ventures") is an exclusive fund created as a platform that seeks to invest in businesses that contribute to the Company's growth strategy and accelerate the journey of digitalization in health.

Dr. Cuco Desenvolvimento de Software Ltda. ("Dr. Cuco") is a digital care platform focused on adherence to treatment.

Impulso Soluções de Mídia Ltda. ("Impulso") is RD's Retail Media solution, a platform that offers a high reach potential through personalized audiences with retail data and high accuracy of results. This allows advertisers to analyze the performance of online and offline campaigns and to be present at all times of the consumer journey.

SafePill Comércio Varejista de Medicamentos Manipulados Ltda. ("Dose Certa + Cuidado") is focused on adherence to treatments and offers services for Management of Self-Care Home Treatments.

ZTO Tecnologia e Serviços de Informação na Internet Ltda. ("Manipulação Raia Drogasil") is the first startup of the Brazilian compounding pharmacies market, operating as a marketplace platform that provides customers with immediate online access to compounding pharmacies.

Kymberg Farmacêutica do Brasil Ltda. ("Kymberg") is a pharmaceutical company specialized in the production of medicines.

RD Saúde holds all the subordinated quotas of RD Fundo de Investimento em Direitos Creditórios Crédito Corporativo ("RD FIDC"). The Company consolidates RD FIDC's financial information because it believes that a significant portion of the risks and rewards related to profitability is linked to the subordinated quotas held by RD Saúde.

Hereinafter, the entities mentioned above will be collectively referred to as "Subsidiaries".

1.1. Sale of subsidiary 4Bio

On March 3, 2026, the Company entered into a Share Purchase and Sale Agreement and Other Covenants for the sale of its entire equity interest in its subsidiary 4Bio Medicamentos S.A. "4Bio" to Health Ventures S.A., a direct subsidiary of Profarma Distribuidora de Produtos Farmacêuticos S.A.

The base value of the transaction is R$ 600 million, including the maintenance, at 4Bio, as of the closing date of the transaction, of net cash of R$ 80 million, in addition to other customary adjustments to working capital and net debt, typical of transactions of this nature. The amount will be paid in six (6) installments, as follows: (i) R$ 100 million on the closing date of the transaction; and (ii) five (5) annual installments of R$ 100 million, adjusted by the CDI.

In addition, the contract provides for the right to recognition of an estimated gain from assets of R$ 127 million, related to the ICMS tax rate differential (DIFAL), for which a favorable ruling has already been issued by the Federal Supreme Court (STF), including a final and unappealable decision for an amount equivalent to R$ 12 million. The funds will be released upon the withdrawal of the judicial deposits, once the decision becomes final.

The sale was completed on May 4, 2026, as described in Note 31.

Further details regarding this transaction, as well as the results of discontinued operations for the periods ended June 30, 2026 and 2025, are provided in Note 30.

2. Presentation of quarterly information

In conformity with NBC TG 24(R2), authorization to issue these financial statements was granted by the Company's Board of Directors on August 4, 2026.

The individual and consolidated interim financial information for the period ended June 30, 2026, included in the Quarterly Information Form (ITR), was prepared in accordance with Technical Pronouncement CPC 21(R1) – Interim Financial Reporting, issued by the Brazilian Accounting Pronouncements Committee (CPC), and in conformity with International Accounting Standard IAS 34 – Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), and discloses all (and only) the applicable significant information related to the financial statements, which is consistent with the information utilized by management in the performance of its duties. The Group adopted all standards, revised standards and interpretations issued by the IFRS and CPC that were effective as of January 1, 2026.

The statement of income, statement of value added, statement of cash flows, and notes to the interim financial information for the six-month period ended June 30, 2025 are being restated due to the sale of the subsidiary 4Bio (Note 1.1), considering the effects of such transactions in accordance with Technical Pronouncement CPC 31 / IFRS 5 – Non-current Assets Held for Sale and Discontinued Operations.

The statements of cash flows include continuing and discontinued operations in accordance with Technical Pronouncement CPC 31/IFRS 5.

The individual interim financial information is disclosed together with the consolidated interim financial information, which includes the interim financial information of the Company and its subsidiaries 4Bio, Dr. Cuco, Manipulação Raia Drogasil, Dose Certa + Cuidado, Impulso, Kymberg, FIP RD Ventures, RD FIDC and RD Log, and have been prepared in accordance with consolidation practices and applicable legal provisions.

The accounting practices adopted by the Subsidiaries were applied uniformly and consistently with those adopted by the Company. Where applicable, all transactions, balances, income and expenses between the Subsidiary and the Company are fully eliminated in the consolidated interim financial information.

This interim financial information was prepared on the historical cost basis, except for: (i) certain financial instruments; and (ii) assets and liabilities arising from business combinations measured at their fair values, when applicable. Historical cost is generally based on the fair value of the consideration paid for goods or services.

The interim financial information includes accounting estimates and requires management to exercise its judgment in the process of applying the Company's accounting policies regarding provision for inventory losses, provision for expected credit losses, appreciation of financial instruments, realization periods of recoverable taxes, the amortization and depreciation periods for fixed and intangible assets, estimate of impairment of intangible assets with indefinite useful life, provision for legal claims, fair value measurement of financial liabilities, determination of provision for taxes, recognition of revenues from commercial agreements, among others. The significant estimates and judgments are disclosed in Note 4(f).

The presentation of the individual and consolidated statements of value added is required by the Brazilian corporate legislation and the accounting practices adopted in Brazil for listed companies, while it is not required by IFRS. Therefore, under the IFRS, the presentation of such statements is considered supplementary information, and not part of the set of the interim financial information.

The interim financial information is presented in thousands of Brazilian reais (R$), which is the Group's functional and presentation currency.

(All amounts in thousands of reais unless otherwise stated)

3. New accounting procedures, amendments to and interpretations of standards

Standards issued but not yet effective

The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the Company's interim financial information are disclosed below. The Company intends to adopt these new and amended standards and interpretations, if applicable, when they become effective.

CBPS 1 / IFRS S1 - General Requirements for Disclosure of Sustainability-related Financial Information; CBPS 2 / IFRS S2 - Climate-related Disclosures	CBPS 1 / IFRS S1 - General Requirements for Disclosure of Sustainability-related Financial Information; This standard is to require an entity to disclose information about its sustainability-related risks and opportunities that is useful to primary users of general purpose financial reports in making decisions relating to providing resources to the entity. The Company is assessing the impact of this standard for early adoption or compliance with the term defined therein. CBPS 2 / IFRS S2 - Climate-related Disclosures The objective of this standard is to establish the requirements to identify, measure and disclose information about climate-related risks and opportunities that is useful to primary users of general purpose financial reports in making decisions relating to providing resources to the entity. Both pronouncements apply to fiscal years beginning on or after January 1, 2026, with voluntary early adoption as from January 1, 2025. The Company is assessing the possible impacts from this implementation on the presentation and disclosure of the interim financial information and has not implemented it early.
IFRS 18 - Presentation and Disclosure in Financial Statements	IFRS 18 - Presentation and Disclosure in Financial Statements replaces IAS 1 – Presentation of Financial Statements in the preparation of financial statements beginning or after January 1, 2027. IFRS 18 (i) introduces new requirements for the presentation of the statement of income, with the inclusion of three new categories of income and expenses - operating, investments and financing - two mandatory subtotals, and changes in the grouping of balances; (ii) requires the disclosure in the explanatory notes of the performance measures defined by Management; and (iii) includes changes in the statement of cash flows and new requirements for the presentation of expenses by nature or function. The Company is assessing the possible impacts from this standard on the presentation and disclosure of the interim financial information.
IFRS 19: Subsidiaries without Public Accountability: Disclosures	In May 2024, the IASB issued IFRS 19, which allows eligible entities to opt to apply reduced disclosure requirements while still applying the recognition, measurement and presentation requirements in other IFRS accounting standards. To be eligible, at the end of the reporting period, an entity must be a subsidiary as defined in IFRS 10 (CPC - 36 (R3) - Consolidated Financial Statements), cannot have public accountability and must have a parent (ultimate or intermediate) that prepares interim financial information, available for public use, that complies with the IFRS Accounting Standards. IFRS 19 will be effective for reporting periods beginning on or after January 1, 2027. The Company is assessing the possible impacts from this standard on the presentation and disclosure of the interim financial information.

Additionally, other accounting standards, amendments and interpretations have been issued recently, however they are not yet effective or did not have a material impact on this interim financial information. For the period ended June 30, 2026, the Company did not early adopt any standard and did not identify a significant impact on the interim financial information.

4. Material accounting practices

The accounting practices adopted in the preparation of this interim financial information were consistently applied in the current period and are consistent with those disclosed in Note 4 and, when related to significant accounting balances, are detailed in the notes to the financial statements for the year ended December 31, 2025, disclosed on March 3, 2026.

(All amounts in thousands of reais unless otherwise stated)

5. Cash and cash equivalents

	Parent Company		Consolidated	
Cash and cash equivalents items	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
Cash and banks	213,618	209,843	227,405	222,229
Repurchase agreements (i)	39,794	-	39,794	55,637
Automatic investments(ii)	69,490	87,122	69,867	104,596
Bank Deposit Certificates - CDB(iii)	-	-	199,435	127,157
Total	**322,902**	**296,965**	**536,501**	**509,619**

(i) Fixed-income investment with income linked to the variation of the Interbank Deposit Certificate - CDI, with immediate liquidity and without loss of income.
(ii) Short-term fixed income fund with short-term investments and automatic redemptions.
(iii) Investments in bank deposit certificate have daily liquidity and grace period of 30 days.

6. Held-to maturity investments

	Parent Company		Consolidated	
Cash and cash equivalents items	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
RD Fundo de Investimento em Direitos Creditórios Corporativos	28,624	28,112	-	-
Investment fund	-	-	116,449	19,120
Total	**28,624**	**28,112**	**116,449**	**19,120**

RD Fundo de Investimento em Direitos Creditórios Corporativos (“RD FIDC”)

The balance of R$ 28,624 in the Parent Company at June 30, 2026 refers to the investment in RD Fundo de Investimento em Direitos Creditórios Corporativos (“RD FIDC”).

RD FIDC began its activities on February 16, 2023, established as a special fund, as provided for by CMN Resolution 2,907, of November 29, 2001, and by CVM Instruction 175/22, of December 23, 2022. On March 28, 2023, the Company made the first contribution to RD FIDC.

RD FIDC's capital structure at June 30, 2026 comprised 169,103 senior quotas held by third parties in the amount of R$ 243,938, representing 92.40% of the fund's equity, and 26,163 subordinated quotas held by RD in the amount of R$ 28,624, representing 7.60% of the fund's equity.

The purpose of RD FIDC is to provide to its quotaholders the valuation of their quotas through the investment of their funds exclusively in credit rights arising from payment transactions carried out by the Company, with the use of payment instruments for the acquisition of goods and services. The earnings of the senior quotas are paid monthly and are subject to a minimum remuneration of CDI plus 1.66% p.a.

Subordinated quotas were attributed to the Company and were recorded in current assets as interest in the securitization fund, with a balance of R$ 28,624 (R$ 28,112 – Dec/25). The subordinated quotas represent the Company’s maximum exposure to the credit risks of the structure; RD Saúde has no additional liability to the senior shareholders, nor is it required to make up for the Fund’s losses.

Obligations related to senior quotas constitute liabilities solely of the Fund itself, and not of RD Saúde. The FIDC, as provided for in CVM Resolution 175, operates with segregated assets and asset autonomy (CVM 175 – Art. 4; §2 of Art. 5), and its obligations are strictly limited to its net assets.

Investment Fund

Balance held by FIP RD Ventures and by RD FIDC in short-term investment funds which aim to provide to its quotaholders the valuation of their quotas through the investment of their funds in a portfolio fully comprised of federal government securities. The investment has no grace period for redemption and convertibility of the quotas, the amount may be readily invested or redeemed and the financial settlement occurs on the same day.

(All amounts in thousands of reais unless otherwise stated)

7. Trade receivables

Trade receivables items	Parent Company Jun/26	Parent Company Dec/25	Consolidated Jun/26	Consolidated Dec/25
Trade receivables	3,019,112	2,799,770	3,137,617	3,462,493
(-) Expected credit losses	(4,221)	(1,745)	(4,243)	(11,900)
(-) Adjustment to present value	(37,625)	(40,037)	(37,625)	(50,008)
Total	**2,977,266**	**2,757,988**	**3,095,749**	**3,400,585**

The detailed aging of trade receivables is presented below:

Maturities	Parent Company Jun/26	Parent Company Dec/25	Consolidated Jun/26	Consolidated Dec/25
Not yet due	3,011,561	2,794,649	3,128,609	3,409,849
Overdue:				
Between 1 and 30 days	3,565	1,470	4,431	21,301
Between 31 and 60 days	1,406	1,515	1,430	6,600
Between 61 and 90 days	864	1,313	864	5,306
Between 91 and 180 days	1,716	823	1,734	6,322
Between 181 and 360 days	-	-	549	13,115
(-) Expected credit losses	(4,221)	(1,745)	(4,243)	(11,900)
(-) Adjustment to present value	(37,625)	(40,037)	(37,625)	(50,008)
Total	**2,977,266**	**2,757,988**	**3,095,749**	**3,400,585**

Days sales outstanding, represented by credit and debit cards and partnerships with companies and the Government, are approximately 45 days (45 days – Dec/2025), term that is considered part of the normal conditions inherent in the Group's operations. A substantial portion of the amounts overdue for more than 31 days is represented by collection through special plans, Medicine Benefit Program (PBM), and Popular Pharmacy Program.

The changes in expected credit losses are presented below:

Changes in expected losses	Parent Company	Consolidated
At January 1, 2025	**(978)**	**(19,169)**
Additions	(16,718)	(29,728)
Reversals	10,371	22,320
Losses	2,608	8,396
At June 30, 2025	**(4,717)**	**(18,181)**
Additions	(11,143)	(22,194)
Reversals	8,161	9,205
Losses	5,954	19,270
At December 31, 2025	**(1,745)**	**(11,900)**
Write-off due to the sale of subsidiaries	-	9,964
Additions	(9,213)	(9,213)
Reversals	3,365	3,534
Losses	3,372	3,372
At June 30, 2026	**(4,221)**	**(4,243)**

Trade receivables are classified as financial assets at amortized cost and are therefore measured as described in Note 26.1 – Impairment to the interim financial information for the period ended June 30, 2026.

(All amounts in thousands of reais unless otherwise stated)

8. Inventories

	Parent Company		Consolidated	
Inventory items	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
Goods for resale	8,463,726	9,301,674	8,468,943	9,748,264
Consumables	2,057	2,579	2,393	2,840
(-) Adjustment to present value	(71,952)	(101,462)	(71,952)	(99,397)
(-) Provision for inventory losses	(65,488)	(75,364)	(65,488)	(75,364)
Total inventories	**8,328,343**	**9,127,427**	**8,333,896**	**9,576,343**

Changes in the provision for expected losses on goods are as follows:

Changes in expected losses on goods	**Parent Company**	**Consolidated**
At January 1, 2025	**(83,413)**	**(83,413)**
Additions	(21,751)	(21,751)
Write-offs	28,458	28,458
At June 30, 2025	**(76,706)**	**(76,706)**
Additions	(19,307)	(19,307)
Write-offs	20,649	20,649
At December 31, 2025	**(75,364)**	**(75,364)**
Additions	(6,423)	(6,423)
Write-offs	16,299	16,299
At June 30, 2026	**(65,488)**	**(65,488)**

For the six-month period ended June 30, 2026, cost of goods sold recognized in the statement of income was R$ 14,491,067 (R$ 13,342,611- Jun/2025) for the Parent Company and R$ 14,503,444 (R$ 14,766,894- Jun/2025) for the Consolidated accounts (Note 23), including the amount of the write-offs of goods inventories recognized as losses for the period amounting to R$ 236,408 (R$ 245,915 - Jun/2025) for the Parent Company and R$ 236,408 (R$ 247,232 - Jun/2025) for the Consolidated.

The effect of the recognition, reversal or write-off of the provision for inventory losses is included in cost of sales in the statement of income.

(All amounts in thousands of reais unless otherwise stated)

9. Recoverable taxes

	Parent Company		Consolidated	
Recoverable taxes items	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
Taxes on profit recoverable				
Withholding Income Tax (IRRF)	1,325	3,798	9,417	7,203
Corporate Income Tax (IRPJ)	34,460	36,215	34,895	43,228
Social Contribution on Net Profit (CSLL)	14,957	14,942	17,947	17,070
Subtotal	**50,742**	**54,955**	**62,259**	**67,501**
Other recoverable taxes				
Value Added Tax on Sales and Services (ICMS) – credit balance (i)	250,244	183,841	250,244	198,961
ICMS – Refund of ICMS withheld in advance (i)	739,755	245,879	739,755	274,626
ICMS on acquisitions of property, plant and equipment items	135,437	137,962	135,764	137,962
Service Tax (ISS)	610	610	610	612
Social Integration Program (PIS)	22,193	20,746	22,210	21,286
Social Contribution on Revenue (COFINS)	92,227	92,922	92,305	95,298
National Institute of Social Security (INSS)	-	-	200	204
Subtotal	**1,240,466**	**681,960**	**1,241,088**	**728,949**
Total	**1,291,208**	**736,915**	**1,303,347**	**796,450**
Current assets	1,054,574	509,584	1,066,713	541,373
Non-current assets	236,634	227,331	236,634	255,077

(i) The ICMS credits amounting to R$ 250,244 and R$ 739,755 (R$ 183,841 and R$ 245,879 - Dec/25) for the Parent Company and R$ 250,243 and R$ 739,755 (R$ 198,961 and R$ 274,626 - Dec/25) for the Consolidated accounts are the result of applying different ICMS rates and of refunds of ICMS-ST (the Substitute Taxpayer Regime). The respective tax credits have been progressively consumed. As of January 1, 2026, perfumery, cosmetics and personal care products are no longer subject to tax substitution, in accordance with SRE Ordinance 09/2025 (DOE 12/23/2025)

Expected realization of credits

The expected realization of amounts classified in current and non-current assets is as follows:

	Parent Company		Consolidated	
Expected realization	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
In the next 12 months	1,054,574	509,584	1,066,713	541,373
Between 13 and 24 months	36,884	42,535	36,884	70,281
Between 25 and 36 months	48,628	58,571	48,628	58,571
Between 37 and 48 months	46,866	56,165	46,866	56,165
Over 48 months	104,256	70,060	104,256	70,060
Total	**1,291,208**	**736,915**	**1,303,347**	**796,450**

(All amounts in thousands of reais unless otherwise stated)

10.Investments

At June 30, 2026, the Company's investment balances are presented below:

		Jun/26			Dec/25		
Investee	**Main activity**	**Interest (%)**	**Parent Company**	**Consolidated**	**Interest (%)**	**Parent Company**	**Consolidated**
Direct interest							
4Bio	Retail of special medicines	100.00%	-	-	100.00%	976,676	-
RD Ventures FIP	Private equity investment fund	100.00%	158,560	-	100.00%	155,086	-
Stix Fidelidade	Platform of products and services for the accumulation and redemption of points	100.00%	63,270	-	33.33%	18,425	18,425
Dr. Cuco	Digital care platform focused on adherence to treatment	100.00%	155,060	-	100.00%	143,523	-
Impulso	Advisory and consultancy in advertising and marketing	100.00%	11,183	-	100.00%	11,581	-
Dose Certa + Cuidado	Management of Self-Care Home Treatments	100.00%	45,285	-	100.00%	44,688	-
Manipulação Raia Drogasil	Marketplace of Compounding Pharmacies	100.00%	23,553	-	100.00%	23,828	-
Kymberg	Pharmaceutical company specialized in the production of medicines	100.00%	16,115	-	100.00%	16,351	-
RD Log	Transportation and logistics company	100.00%	-	-	100.00%	-	-
Indirect interest							
Labi	Healthtech focused on laboratory tests, tests, check-ups and vaccines.	24.669%	-	(1,255)	25.01%	-	1,038
Total			**473,026**	**(1,255)**		**1,390,158**	**19,463**
Reclassification to “Other liabilities”, as provision for losses on investments			**-**	**1,255**		**-**	**-**
Classified as investments			**473,026**	**-**		**1,390,158**	**19,463**

Voltar

(All amounts in thousands of reais unless otherwise stated)

Changes in investment balances presented in the interim financial information are shown below:

Changes in investments	4BIO	stix	RD Ventures	Impulso	Cuco Health	dose certa +cuidado SafePill	Drogasil manipulação / Raia manipulação	Kymberg	RD Log	**Total**
	Subsidiary	Subsidiary	Subsidiary	Subsidiary	Subsidiary	Subsidiary	Subsidiary	Subsidiary	Subsidiary	
At January 1, 2025	**733,451**	**9,475**	**169,200**	**123,132**	**15,061**	**40,493**	**20,285**	**17,930**	**16**	**1,129,043**
Capital contribution	60,000	-	17,850	-	120	8,000	6,700	-	-	**92,670**
Equity in the results of subsidiaries	81,386	2,022	(1,762)	10,321	(3,143)	(4,746)	(5,151)	(1,719)	(8)	**77,200**
Restricted share compensation plan	(331)	-	-	(10)	-	-	-	-	-	**(341)**
At June 30, 2025	**874,506**	**11,497**	**185,288**	**133,443**	**12,038**	**43,747**	**21,834**	**16,211**	**8**	**1,298,572**
Capital contribution	-	-	6,600	-	-	5,500	6,000	1,500	-	**19,600**
Write-off of investment	-	-	-	-	-	-	-	-	(6)	**(6)**
Equity in the results of subsidiaries	102,170	6,928	(36,802)	10,079	(457)	(4,559)	(4,006)	(1,360)	(2)	**71,991**
Restricted share compensation plan	-	-	-	1	-	-	-	-	-	**1**
At December 31, 2025	**976,676**	**18,425**	**155,086**	**143,523**	**11,581**	**44,688**	**23,828**	**16,351**	**-**	**1,390,158**
Capital contribution	-	-	3,620	-	100	4,500	3,000	1,000	-	**12,220**
Business combinations	-	42,568	-	-	-	-	-	-	-	**42,568**
Equity in the results of subsidiaries	20,142	2,276	(146)	11,536	(497)	(3,902)	(3,275)	(1,236)	-	**24,898**
Write-off of investment	(996,818)	-	-	-	-	-	-	-	-	**(996,818)**
At June 30, 2026	**-**	**63,269**	**158,560**	**155,059**	**11,184**	**45,286**	**23,553**	**16,115**	**-**	**473,026**

(All amounts in thousands of reais unless otherwise stated)

For the purpose of calculating the equity in subsidiaries and associates, the Company adjusts the assets, liabilities and the respective changes in the result. At 4Bio they are adjusted based on the purchase price allocation determined at the acquisition date. The table below shows the effects on profit (loss) for the period of subsidiaries and associate for the purposes of determining the equity in the results of subsidiaries for the periods ended June 30, 2026 and 2025:

Changes in equity in the results of subsidiaries	4BIO	stix	RD Ventures	impulso	cuco Health	dose certa SafePill	Drogasil Raia manipulação	Kymberg	RD Log	**Total**
Profit (loss) for the period	183,762	8,950	(38,564)	20,400	(2,761)	(9,305)	(7,998)	(3,079)	(10)	**151,395**
Amortization of surplus value arising from business combination	(206)	-	-	-	(839)	-	(1,159)	-	-	**(2,204)**
Equity in the results of subsidiaries at 12/31/2025	**183,556**	**8,950**	**(38,564)**	**20,400**	**(3,600)**	**(9,305)**	**(9,157)**	**(3,079)**	**(10)**	**149,191**
Profit (loss) for the period	20,211	2,276	(146)	11,536	(78)	(3,902)	(2,696)	(1,236)	-	**25,965**
Amortization of surplus value arising from business combination	(69)	-	-	-	(419)	-	(579)	-	-	**(1,067)**
Equity in the results of subsidiaries at 6/30/2026	**20,142**	**2,276**	**(146)**	**11,536**	**(497)**	**(3,902)**	**(3,275)**	**(1,236)**	**-**	**24,898**

(All amounts in thousands of reais unless otherwise stated)

Adjusted equity	stix	RD VENTURES	impulso	CUCO HEALTH	dose certa +cuidado SafePill	DROGASIL manipulação Raia manipulação	Kymberg	Jun/26
Investment at book value	62,112	158,560	155,196	(1,634)	11,303	5,313	3,417	**394,267**
Purchase price allocation (surplus value of assets)	1,158	-	-	2,321	-	5,844	-	**9,323**
Restricted share compensation plan	-	-	(136)	-	-	-	-	**(136)**
Total adjusted equity	**63,270**	**158,560**	**155,060**	**687**	**11,303**	**11,157**	**3,417**	**403,454**
Goodwill based on expected future profitability	-	-	-	10,496	33,982	12,396	12,698	**69,572**
Investment balance	**63,270**	**158,560**	**155,060**	**11,183**	**45,285**	**23,553**	**16,115**	**473,026**

Adjusted equity	4BIO	stix	RD VENTURES	impulso	CUCO HEALTH	dose certa +cuidado SafePill	DROGASIL manipulação Raia manipulação	Kymberg	Dec/25
Investment at book value	962,908	18,425	155,086	143,659	(1,236)	10,706	5,588	3,653	**1,298,789**
Purchase price allocation (surplus value of assets)	2,167	-	-	-	2,321	-	5,844	-	**10,332**
Deferred income tax liability on allocation adjustments	(821)	-	-	-	-	-	-	-	**(821)**
Restricted share compensation plan	(485)	-	-	(136)	-	-	-	-	**(621)**
Total adjusted equity	**963,769**	**18,425**	**155,086**	**143,523**	**1,085**	**10,706**	**11,432**	**3,653**	**1,307,679**
Goodwill based on expected future profitability	12,907	-	-	-	10,496	33,982	12,396	12,698	**82,479**
Investment balance	**976,676**	**18,425**	**155,086**	**143,523**	**11,581**	**44,688**	**23,828**	**16,351**	**1,390,158**

10.1. Business combinations

On May 19, 2026, RD and Companhia Brasileira de Distribuição "GPA" entered into a Share Purchase and Sale Agreement and Other Covenants in which RD acquired all the shares of STIX FIDELIDADE E INTELIGÊNCIA S.A "Stix" held by GPA.

Stix was founded in 2018 and has a noncontrolling interest (33.33%) held by RD Saúde since 2019, Stix operates in the structuring, development, operation and management of loyalty program organized in the form of a coalition that brings together several players and enables the accumulation, management, sale and redemption of loyalty points. The base value of the transaction was R$ 23,000 for the acquisition of 66.7% of the shares of Stix, with no price adjustments, and was paid in two installments: (i) R$ 2,300 on the date of signing the purchase and sale agreement (June 30, 2026); and (ii) 20,700 million two days after the closing of the transaction. In the statement of cash flows, the amount of R$ 2,300 paid to the former shareholder is presented under "Acquisition and capital contribution in investees".

(All amounts in thousands of reais unless otherwise stated)

On June 30, the suspensive conditions set out in the Agreement were properly fulfilled or waived, and the Parties consummated the Closing of the transaction. On July 2, 2026, RD settled the transaction with GPA.

Assets	Jun/26	Liabilities	Jun/26
Cash and cash equivalents	143,214	Suppliers	61,007
Trade receivables	63,116	Salaries and social charges	22,852
Recoverable taxes	5,463	Taxes and contributions	1,746
Other assets	6,022	Other liabilities	55,023
Deferred income tax and social contribution	7,737	Deferred revenue	69,270
Property, plant and equipment	601	**Total liabilities**	**209,898**
Intangible assets	45,856	**Net assets and liabilities**	**62,111**
Total assets	**272,009**	**Total liabilities and equity**	**272,009**

As required by CPC 15 (R1)/ IFRS 3 – Business Combinations, all identifiable assets acquired and liabilities assumed were measured and recognized at their respective fair values on the transaction closing date.

As a result of the detailed assessment carried out by an independent expert, the net fair value (preliminary) of the identifiable assets and liabilities assumed exceeded the total consideration transferred, generated a bargain purchase gain recorded in the statement of income under " Other operating income/(expenses)".

Before the final recognition of this gain, the Company's management reviewed the process for identification and measurement of all assets acquired and liabilities assumed, as well as the assessment of the consideration transferred, confirming that all related elements were properly reflected in the accounting records.

The table below summarizes the consideration transferred, the fair values of the assets acquired and liabilities assumed on the transaction date, and the resulting bargain purchase gain:

Consideration	23,000
Net assets and liabilities – Jun/26	62,111
Surplus value - Software - Useful life of 7 years	1,709
Net assets and liabilities assumed (66.7%)	42,568
Gain on bargain purchase	19,568

The acquisition was completed on June 30. On that date, Stix became a wholly-owned subsidiary of RD, being consolidated by the Company.

(All amounts in thousands of reais unless otherwise stated)

11.Property, plant and equipment

11.1. Breakdown and changes

Fixed assets are broken down as follows:

		Parent Company					
		Jun/26			Dec/25		
	Average annual depreciation rates (%)	Cost	Accumulated depreciation	Net book value	Cost	Accumulated depreciation	Net book value
Land	-	32,124	-	**32,124**	32,124	-	**32,124**
Buildings	2.5 - 2.7	69,837	(36,667)	**33,170**	69,837	(35,800)	**34,037**
Furniture, fittings and facilities	7.4 - 10	2,031,499	(939,458)	**1,092,041**	2,106,499	(1,037,949)	**1,068,550**
Machinery and equipment	7.1 - 15.8	1,228,306	(783,962)	**444,344**	1,240,407	(790,440)	**449,967**
Vehicles	20 - 23.7	220,220	(140,813)	**79,407**	219,295	(125,658)	**93,637**
Property improvements	13 - 20	3,704,781	(2,456,414)	**1,248,367**	3,454,570	(2,241,529)	**1,213,041**
Total		**7,286,767**	**(4,357,314)**	**2,929,453**	**7,122,732**	**(4,231,376)**	**2,891,356**

		Consolidated					
		Jun/26			Dec/25		
	Average annual depreciation rates (%)	Cost	Accumulated depreciation	Net book value	Cost	Accumulated depreciation	Net book value
Land	-	32,124	-	**32,124**	32,124	-	**32,124**
Buildings	2.5 - 2.7	69,837	(36,667)	**33,170**	69,837	(35,800)	**34,037**
Furniture, fittings and facilities	7.4 - 10	2,041,607	(940,841)	**1,100,766**	2,118,609	(1,040,619)	**1,077,990**
Machinery and equipment	7.1 - 15.8	1,276,496	(805,030)	**471,466**	1,295,267	(812,391)	**482,876**
Vehicles	20 - 23.7	220,221	(140,814)	**79,407**	219,296	(125,659)	**93,637**
Property improvements	13 - 20	3,711,723	(2,458,610)	**1,253,113**	3,469,561	(2,247,345)	**1,222,216**
Total		**7,352,008**	**(4,381,962)**	**2,970,046**	**7,204,694**	**(4,261,814)**	**2,942,880**

(All amounts in thousands of reais unless otherwise stated)

Changes in the Parent Company's fixed assets are as follows:

Changes in cost	Jan 1/2025	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Jun/25	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/25	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Jun/26
Land	**32,124**	-	-	-	**32,124**	-	-	-	**32,124**	-	-	-	**32,124**
Buildings	**69,837**	-	-	-	**69,837**	-	-	-	**69,837**	-	-	-	**69,837**
Furniture, fittings and facilities	**1,893,280**	110,481	(3,390)	279	**2,000,650**	182,683	(76,647)	(187)	**2,106,499**	120,392	(193,796)	(1,596)	**2,031,499**
Machinery and equipment	**1,127,256**	74,751	(9,666)	-	**1,192,341**	87,884	(39,818)	-	**1,240,407**	54,561	(66,662)	-	**1,228,306**
Vehicles	**213,150**	3,206	(1,428)	-	**214,928**	5,063	(696)	-	**219,295**	2,433	(1,508)	-	**220,220**
Property improvements	**2,917,284**	239,336	(7,182)	2,952	**3,152,390**	308,364	(4,172)	(2,012)	**3,454,570**	270,184	(11,498)	(8,475)	**3,704,781**
Total	**6,252,931**	**427,774**	**(21,666)**	**3,231**	**6,662,270**	**583,994**	**(121,333)**	**(2,199)**	**7,122,732**	**447,570**	**(273,464)**	**(10,071)**	**7,286,767**

Changes in accumulated depreciation	Jan 1/2025	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Jun/25	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Dec/25	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Jun/26
Buildings	**(34,056)**	(872)	-	-	**(34,928)**	(872)	-	-	**(35,800)**	(867)	-	-	**(36,667)**
Furniture, fittings and facilities	**(939,408)**	(85,373)	2,171	296	**(1,022,314)**	(90,536)	74,907	(6)	**(1,037,949)**	(94,897)	192,855	533	**(939,458)**
Machinery and equipment	**(719,864)**	(58,937)	8,647	-	**(770,154)**	(59,293)	39,007	-	**(790,440)**	(59,752)	66,230	0	**(783,962)**
Vehicles	**(94,344)**	(16,795)	1,415	-	**(109,724)**	(16,629)	695	-	**(125,658)**	(16,654)	1,499	0	**(140,813)**
Property improvements	**(1,825,804)**	(203,808)	2,932	(629)	**(2,027,309)**	(218,427)	2,869	1,338	**(2,241,529)**	(229,511)	9,282	5,344	**(2,456,414)**
Total	**(3,613,476)**	**(365,785)**	**15,165**	**(333)**	**(3,964,429)**	**(385,757)**	**117,478**	**1,332**	**(4,231,376)**	**(401,681)**	**269,866**	**5,877**	**(4,357,314)**

(All amounts in thousands of reais unless otherwise stated)

Changes in the Consolidated fixed assets are as follows:

Changes in cost	Jan 1/2025	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Jun/25	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/25	Additions	Additions by business combination	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Jun/26
Land	**32,124**	-	-	-	**32,124**	-	-	-	**32,124**	-	-	-	-	**32,124**
Buildings	**69,837**	-	-	-	**69,837**	-	-	-	**69,837**	-	-	-	-	**69,837**
Furniture, fittings and facilities	**1,903,450**	110,780	(3,390)	279	**2,011,119**	184,461	(76,784)	(187)	**2,118,609**	120,912	105	(196,423)	(1,596)	**2,041,607**
Machinery and equipment	**1,171,390**	79,742	(9,666)	-	**1,241,466**	95,735	(41,934)	-	**1,295,267**	56,758	838	(76,367)	-	**1,276,496**
Vehicles	**213,151**	3,206	(1,428)	-	**214,929**	5,063	(696)	-	**219,296**	2,433	-	(1,508)	-	**220,221**
Property improvements	**2,925,729**	242,057	(7,181)	2,952	**3,163,557**	312,506	(4,490)	(2,012)	**3,469,561**	270,259	73	(19,695)	(8,475)	**3,711,723**
Total	**6,315,681**	**435,785**	**(21,665)**	**3,231**	**6,733,032**	**597,765**	**(123,904)**	**(2,199)**	**7,204,694**	**450,362**	**1,016**	**(293,993)**	**(10,071)**	**7,352,008**

Changes in accumulated depreciation	Jan 1/2025	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Jun/25	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Dec/25	Additions	Additions by business combination	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Jun/26
Buildings	**(34,056)**	(872)	-	-	**(34,928)**	(872)	-	-	**(35,800)**	(867)	-	-	-	**(36,667)**
Furniture, fittings and facilities	**(941,315)**	(85,752)	2,172	296	**(1,024,599)**	(90,967)	74,953	(6)	**(1,040,619)**	(95,252)	(45)	194,542	533	**(940,841)**
Machinery and equipment	**(733,166)**	(63,046)	8,647	-	**(787,565)**	(63,931)	39,105	-	**(812,391)**	(64,330)	(360)	72,051	-	**(805,030)**
Vehicles	**(94,345)**	(16,795)	1,415	-	**(109,725)**	(16,629)	695	-	**(125,659)**	(16,654)	-	1,499	-	**(140,814)**
Property improvements	**(1,830,127)**	(204,200)	2,932	(629)	**(2,032,024)**	(219,750)	3,091	1,338	**(2,247,345)**	(230,339)	(11)	13,741	5,344	**(2,458,610)**
Total	**(3,633,009)**	**(370,665)**	**15,166**	**(333)**	**(3,988,841)**	**(392,149)**	**117,844**	**1,332**	**(4,261,814)**	**(407,442)**	**(416)**	**281,833**	**5,877**	**(4,381,962)**

(All amounts in thousands of reais unless otherwise stated)

11.2. Changes in the provision for pharmacies closure

The changes in the Parent Company's provision for pharmacies closure are shown below:

	Provision	Depreciation	Total properties
At January 1, 2025	**(4,672)**	**1,444**	**(3,228)**
Additions	(1,441)	1,111	(330)
Reversals	4,672	(1,444)	3,228
At June 30, 2025	**(1,441)**	**1,111**	**(330)**
Additions	(3,642)	2,444	(1,198)
Reversals	1,443	(1,112)	331
At December 31, 2025	**(3,640)**	**2,443**	**(1,197)**
Additions	(13,711)	8,320	(5,391)
Reversals	3,640	(2,443)	1,197
Changes, net	**(10,071)**	**5,877**	**(4,194)**
At June 30, 2026	**(13,711)**	**8,320**	**(5,391)**

(All amounts in thousands of reais unless otherwise stated)

12. Intangible assets

12.1. Breakdown and changes

		Parent Company					
	Average annual amortization rates (%)	Jun/26			Dec/25		
		Cost	Accumulated amortization	Net book value	Cost	Accumulated amortization	Net book value
Key money	17 - 23.4	311,594	(276,608)	**34,986**	310,069	(273,566)	**36,503**
Software license	20	1,674,912	(925,381)	**749,531**	1,560,057	(793,471)	**766,586**
Goodwill on business acquisition – Vison	(i)	22,275	(2,387)	**19,888**	22,275	(2,387)	**19,888**
Goodwill on business acquisition – Raia	(i)	780,084	-	**780,084**	780,084	-	**780,084**
Trademarks with finite useful life	20	9,311	(1,593)	**7,718**	18,453	(10,619)	**7,834**
Trademarks with indefinite useful life	(i)	151,000	-	**151,000**	151,000	-	**151,000**
Customers portfolio (Raia S.A.)	6.7 - 25	41,700	(41,547)	**153**	41,700	(41,317)	**383**
Total		**2,990,876**	**(1,247,516)**	**1,743,360**	**2,883,638**	**(1,121,360)**	**1,762,278**

		Consolidated					
	Average annual amortization rates (%)	Jun/26			Dec/25		
		Cost	Accumulated amortization	Net book value	Cost	Accumulated amortization	Net book value
Key money	17 - 23.4	311,594	(276,609)	**34,985**	311,966	(273,563)	**38,403**
Software license	20	1,822,561	(1,007,991)	**814,570**	1,605,236	(812,643)	**792,593**
Goodwill on acquisitions of investees	(i)	1,025,032	(2,387)	**1,022,645**	1,050,593	(2,387)	**1,048,206**
Platform	20	8,886	(2,045)	**6,841**	8,886	(2,045)	**6,841**
Non-compete agreement	20	363	(363)	**-**	833	(345)	**488**
Trademarks with finite useful life	20	12,679	(4,480)	**8,199**	29,344	(19,868)	**9,476**
Trademarks with indefinite useful life	(i)	151,000	-	**151,000**	151,000	-	**151,000**
Customers portfolio (Raia S.A.)	6.7 - 25	41,700	(41,547)	**153**	41,700	(41,317)	**383**
Customer relationship	20	824	(824)	**-**	9,395	(5,222)	**4,173**
Total		**3,374,639**	**(1,336,246)**	**2,038,393**	**3,208,953**	**(1,157,390)**	**2,051,563**

(i) Assets with indefinite useful lives

(All amounts in thousands of reais unless otherwise stated)

Changes in the Company's intangible assets are as follows:

Changes in cost	Jan 1/2025	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Jun/25	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/25	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Jun/26
Key money	**296,437**	5,659	(18)	35	**302,113**	8,026	(35)	(35)	**310,069**	6,708	(3,748)	(1,435)	**311,594**
Software license and systems implementation	**1,322,318**	132,055	(1,529)	-	**1,452,844**	201,124	(93,911)	-	**1,560,057**	114,855	-	-	**1,674,912**
Goodwill on business acquisition – Vison	**22,275**	-	-	-	**22,275**	-	-	-	**22,275**	-	-	-	**22,275**
Goodwill on business acquisition – Raia	**780,084**	-	-	-	**780,084**	-	-	-	**780,084**	-	-	-	**780,084**
Trademarks with finite useful life	**22,232**	-	(7,036)	-	**15,196**	-	3,257	-	**18,453**	-	(9,142)	-	**9,311**
Trademarks with indefinite useful life	**151,000**	-	-	-	**151,000**	-	-	-	**151,000**	-	-	-	**151,000**
Customers portfolio	**41,700**	-	-	-	**41,700**	-	-	-	**41,700**	-	-	-	**41,700**
Total	**2,636,046**	**137,714**	**(8,583)**	**35**	**2,765,212**	**209,150**	**(90,689)**	**(35)**	**2,883,638**	**121,563**	**(12,890)**	**(1,435)**	**2,990,876**

Changes in accumulated amortization	Jan 1/2025	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Jun/25	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Dec/25	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Jun/26
Key money	**(256,434)**	(8,878)	7	(15)	**(265,320)**	(8,288)	15	27	**(273,566)**	(8,070)	3,744	1,284	**(276,608)**
Software license	**(592,881)**	(107,448)	232	-	**(700,097)**	(147,478)	54,104	-	**(793,471)**	(131,910)	-	-	**(925,381)**
Goodwill on business acquisition – Vison	**(2,387)**	-	-	-	**(2,387)**	-	-	-	**(2,387)**	-	-	-	**(2,387)**
Trademarks with finite useful life	**(14,163)**	(476)	3,793	-	**(10,846)**	227	-	-	**(10,619)**	(116)	9,142	-	**(1,593)**
Customers portfolio	**(40,857)**	(230)	-	-	**(41,087)**	(230)	-	-	**(41,317)**	(230)	-	-	**(41,547)**
Total	**(906,722)**	**(117,032)**	**4,032**	**(15)**	**(1,019,737)**	**(155,769)**	**54,119**	**27**	**(1,121,360)**	**(140,326)**	**12,886**	**1,284**	**(1,247,516)**

(All amounts in thousands of reais unless otherwise stated)

Changes in the Consolidated intangible assets are as follows:

Changes in cost	Jan 1/2025	Additions	Transfer	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Jun/25	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/25	Additions	Additions by business combination	Transfer	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Jun/26
Key money	298,334	5,659	-	(18)	35	304,010	8,026	(35)	(35)	311,966	6,708	-	(1,897)	(3,748)	(1,435)	311,594
Software license	1,354,161	135,470	8,422	(1,529)	-	1,496,524	218,869	(110,157)	-	1,605,236	118,197	118,285	13,344	(32,501)	-	1,822,561
Goodwill on acquisitions of investees	1,059,015	-	(8,422)	-	-	1,050,593	-	-	-	1,050,593	-	-	2	(25,563)	-	1,025,032
Surplus value - Platform	8,886	-	-	-	-	8,886	-	-	-	8,886	-	-	-	-	-	8,886
Non-compete agreement	833	-	-	-	-	833	-	-	-	833	-	-	(470)	-	-	363
Trademarks with finite useful life	33,123	-	-	(7,036)	-	26,087	-	3,257	-	29,344	-	-	(5,479)	(11,186)	-	12,679
Trademarks with indefinite useful life	151,000	-	-	-	-	151,000	-	-	-	151,000	-	-	-	-	-	151,000
Customers portfolio - Raia	41,700	-	-	-	-	41,700	-	-	-	41,700	-	-	-	-	-	41,700
Customer relationship	9,395	-	-	-	-	9,395	-	-	-	9,395	-	-	(5,505)	(3,066)	-	824
Total	**2,956,447**	**141,129**	**-**	**(8,583)**	**35**	**3,089,028**	**226,895**	**(106,935)**	**(35)**	**3,208,953**	**124,905**	**118,285**	**(5)**	**(76,064)**	**(1,435)**	**3,374,639**

Changes in accumulated amortization	Jan 1/2025	Additions	Transfer	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Jun/25	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/25	Additions	Additions by business combination	Transfer	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Jun/26
Key money	(256,431)	(8,878)	-	7	(15)	(265,317)	(8,288)	15	27	(273,563)	(8,070)	-	(3)	3,743	1,284	(276,609)
Software license	(602,995)	(109,505)	-	232	-	(712,268)	(155,884)	55,509	-	(812,643)	(133,678)	(71,271)	(6,447)	16,048	-	(1,007,991)
Goodwill on acquisitions of investees	(2,387)	-	-	-	-	(2,387)	-	-	-	(2,387)	-	-	-	-	-	(2,387)
Surplus value - Platform	(1,647)	(199)	-	-	-	(1,846)	(199)	-	-	(2,045)	-	-	-	-	-	(2,045)
Non-compete agreement	-	-	-	-	-	-	(345)	-	-	(345)	(18)	-	-	-	-	(363)
Trademarks with finite useful life	(22,334)	(212)	-	3,793	-	(18,753)	(1,115)	-	-	(19,868)	(116)	-	4,639	10,865	-	(4,480)
Customers portfolio - Raia	(40,857)	(230)	-	-	-	(41,087)	(230)	-	-	(41,317)	(230)	-	-	-	-	(41,547)
Customer relationship	(4,192)	(103)	-	-	-	(4,295)	(927)	-	-	(5,222)	-	-	1,815	2,583	-	(824)
Total	**(930,843)**	**(119,127)**	**-**	**4,032**	**(15)**	**(1,045,953)**	**(166,988)**	**55,524**	**27**	**(1,157,390)**	**(142,112)**	**(71,271)**	**4**	**33,239**	**1,284**	**(1,336,246)**

(All amounts in thousands of reais unless otherwise stated)

12.2. Goodwill on the acquisition of companies

Goodwill on the acquisition of companies is subject to annual impairment testing.

Company	Goodwill amount	Acquisition
Drogaria Vison Ltda.	19,888	2/13/2008
Raia S.A.	780,084	11/10/2011
Dr. Cuco Desenvolvimento de Software Ltda.	10,496	11/19/2021
Healthbit Performasys Tecnologia Inteligência S.A.	17,505	3/09/2021
Amplisoftware Tecnologia Ltda.	82,895	12/22/2021
Labi Exames S.A.	52,328	8/05/2022
SafePill Comércio Varejista de Medicamentos Manipulados Ltda.	33,982	11/23/2022
ZTO Tecnologia e Serviços de Informação na Internet Ltda.	12,396	11/28/2022
Healthbit Serviços Médicos Ltda.	98	2/27/2023
Raia Drogasil Farmácia e Manipulação Ltda.	275	2/28/2023
Kymberg Farmacêutica do Brasil Ltda.	12,698	10/02/2023

The Company reviewed the criteria used to assess the impairment test as of December 31, 2025, and concluded that no events had occurred that would indicate impairment or the need for a new assessment as of June 30, 2026.

12.3. Changes in the provision for pharmacies closure

The changes in the Parent Company's provision for pharmacies closure are shown below:

	Provision	Amortization	Total intangible assets
At January 1, 2025	**(35)**	**15**	**(20)**
Additions	-	-	-
Reversals	35	(15)	20
At June 30, 2025	**-**	**-**	**-**
Additions	(35)	27	(8)
Reversals	-	-	-
At December 31, 2025	**(35)**	**27**	**(8)**
Additions	(1,470)	1,311	(159)
Reversals	35	(27)	8
Changes, net	**(1,435)**	**1,284**	**(151)**
At June 30, 2026	**(1,470)**	**1,311**	**(159)**

(All amounts in thousands of reais unless otherwise stated)

13.Employee benefits

(a) Profit sharing program

The Group has a profit sharing and bonus program intended mainly to measure the performance of employees during the year. Both programs have a formal plan and the amounts payable may be reasonably estimated before the information preparation period, and settled in the short term. On a monthly basis, a liability and an expense for profit sharing are recognized in the statement of income based on estimates of achievement of operating targets and specific objectives established and approved by Management. The recognition as liabilities is made in the account of salaries and social charges and in the statement of income the recognition is made in the accounts of selling expenses and general and administrative expenses (Note 23).

(b) Other benefits

Other short-term benefits are also granted to employees, such as life insurance, health and dental care, housing allowance, funeral assistance, maternity leave and scholarship, which are recognized on an accrual basis and whose right is extinguished at the end of the employment relationship with the Group. The Group does not grant post-employment benefits such as "Plano Gerador de Benefício Livre" (PGBL), "Vida Gerador de Benefício Livre" (VGBL), defined benefit pension plan and/or any retirement or post-employment assistance plan, severance pay benefits or other long-term benefits. Part of the benefits granted to the officers include a restricted share plan, classified as an equity instrument. The fair value of share-based payments is recognized in profit or loss in accordance with the granting period, against equity (see Note 21 d).

14.Suppliers

14.1. Balance breakdown

	Parent Company		Consolidated	
Supplier items	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
Goods suppliers	5,890,715	6,033,798	5,743,761	6,291,086
Service providers	386,680	419,854	403,467	424,334
Materials suppliers	38,411	51,031	38,411	51,255
Assets suppliers	16,610	25,576	16,610	26,002
Adjustment to present value	(81,472)	(104,510)	(81,472)	(112,027)
Total	**6,250,944**	**6,425,749**	**6,120,777**	**6,680,650**

14.2. Suppliers

The Company maintains an arrangement with RD FIDC that allows suppliers to discount their receivables from RD directly with RD FIDC and obtain early liquidity, while RD Saúde remains responsible for settling the notes on the date originally agreed upon with each supplier. In the parent company, the amount of R$ 151,555 (R$ 245,561 in 2025) remained recorded under "Goods suppliers" at June 30, 2026.

At June 30, 2026, the Company had not entered into any forfait transactions with financial institutions.
The Company's Management, based on NBC TG 03 (R3) - Statement of Cash Flows and NBC TG 40 (R2) - Financial Instruments: Disclosures, considered the qualitative aspects on the issue and concluded that there are no significant impacts since the economic substance of the transaction is maintained as an operating activity and there are no changes in the conditions originally agreed with suppliers, such as in the original maturities and amounts.

In the consolidated interim financial information, these amounts are classified as "Liabilities with senior quotaholders - FIDC," as they represent financial obligations to the holders of senior quotas in RD FIDC, as described in Note 15.

15.Liabilities with senior shareholders

The RD FIDC was established on February 16, 2023, for an indefinite term, with the objective of facilitating the advance of receivables from the Company's suppliers through the assignment of receivable rights directly to the fund. The transaction allows suppliers to obtain early liquidity, while RD Saúde remains responsible for settling the notes on the date originally agreed upon with each supplier. The Company, in turn, receives a portion of the discount from the transaction. This revenue totaled R$ 4,102 for the six-month period ended June 30, 2026 (R$ 3,895 in June/2025) and is recorded under general and administrative expenses, in accordance with the supplier's classification. Senior quotas rose by R$ 8,781 during the period (R$ 7,633 in June/2025).

In the operational structure of advance of receivables:

The credit risk considered is that of the Company itself;
The terms and conditions originally agreed upon with the suppliers remain unchanged following the assignment to the FIDC;
There are no additional obligations or financial costs for the Company arising from this transaction.

At June 30, 2026, the balance of senior quotas totaled R$ 243,938 (R$ 211,832 - June/2025).

These amounts are classified as "Liabilities with senior quotaholders - FIDC," as they represent financial obligations to the holders of senior quotas in RD FIDC. Cash flows related to contributions and redemptions of quotas, as well as the payment of remuneration to senior quotaholders, are presented as financing activities in the Statement of Cash Flows. The Company reviewed the covenants in its existing loan and financing agreements and concluded that the outstanding balance of liabilities with senior quotaholders is not included in the Company's net debt at June 30, 2026.

(All amounts in thousands of reais unless otherwise stated)

16. Borrowings and debentures

(a) Breakdown

Borrowings items	Average annual long-term interest rate	Parent Company Jun/26	Parent Company Dec/25	Consolidated Jun/26	Consolidated Dec/25
Debentures					
3rd issue of debentures - CRIs	98.50% of CDI	-	129,940	-	129,940
4th issue of debentures	106.99% of CDI	150,684	301,501	150,684	301,501
5th issue of debentures	100.00% of CDI + 1.49% p.a.	531,804	534,153	531,804	534,153
6th issue of debentures - CRIs	100.00% of CDI + 0.70% p.a.	129,827	260,579	129,827	260,579
7th issue of debentures - CRIs	100.00% of CDI + 0.75% p.a.	544,405	543,732	544,405	543,732
8th issue of debentures - CRIs – 2nd series	100.00% of CDI + 0.65% p.a.	155,415	155,494	155,415	155,494
8th issue of debentures - CRIs – 3rd series	100.00% of CDI + 1.10% p.a.	203,239	203,173	203,239	203,173
9th issue of debentures	100.00% of CDI + 0.65% p.a.	614,630	615,366	614,630	615,366
10th issue of debentures	100.00% of CDI + 0.60% p.a.	513,147	514,080	513,147	514,080
11th issue of debentures	100.00% of CDI + 0.44% p.a.	609,498	609,737	609,498	609,737
Total debentures		**3,452,649**	**3,867,755**	**3,452,649**	**3,867,755**
Current liabilities		365,266	508,137	365,266	508,137
Non-current liabilities		3,087,383	3,359,618	3,087,383	3,359,618

(All amounts in thousands of reais unless otherwise stated)

The amounts above have the following payment flow forecast:

	Parent Company		Consolidated	
Payment forecast	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
2026	92,453	508,137	92,453	508,137
2027	420,475	419,898	420,475	419,898
2028	520,560	520,559	520,560	520,559
2029 and thereafter	2,419,161	2,419,161	2,419,161	2,419,161
Total	**3,452,649**	**3,867,755**	**3,452,649**	**3,867,755**

(b) Characteristics of the debentures

Debentures

Type of issue	Issue amount	Quantity outstanding	Issue	Maturity	Annual charges	Unit price
4th issue – Single Series	R$ 300,000	300,000	6/17/2019	Jun/2027	106.99% of CDI	R$ 1
5th issue – Single Series	R$ 500,000	500,000	1/25/2022	Jan/2029	100% of CDI + 1.49% p.a.	R$ 1
6th issue – Single Series	R$ 250,000	250,000	3/07/2022	Mar/2027	100% of CDI + 0.70% p.a.	R$ 1
7th issue – Single Series	R$ 550,000	550,000	6/26/2022	Jun/2029	100% of CDI + 0.75% p.a.	R$ 1
8th issue - 2nd series	R$ 150,000	150,000	9/15/2023	Sept/2027	100% of CDI + 0.65% p.a.	R$ 1
8thissue - 3rd series	R$ 200,000	200,000	9/15/2023	Sept/2030	100% of CDI + 1.10% p.a.	R$ 1
9th issue – Single Series	R$ 600,000	600,000	4/22/2024	Apr/2031	100% of CDI + 0.65% p.a.	R$ 1
10th issue – Single Series	R$ 500,000	500,000	4/15/2025	Apr/2032	100% of CDI + 0.60% p.a.	R$ 1
11th issue – Single Series	R$ 600,000	600,000	11/10/2025	Nov/2032	100% of CDI + 0.44% p.a.	R$ 1

(*) Weighted average rate of series.

On June 17, 2019, the Company carried out the 4th issue of non-convertible, simple unsecured debentures, in a single series, for public distribution with restricted efforts (CVM 476), with settlement on July 12, 2019, in the amount of R$ 300,000, with remuneration of 106.99% of CDI and payment term of eight years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on June 17, 2027. The funds were used to improve the working capital.

On January 25, 2022, the Company carried out the 5th issue of non-convertible, simple unsecured debentures, in a single series, for public distribution with restricted efforts (CVM 476), with settlement on February 16, 2022, in the amount of R$ 500,000, with remuneration of 100% of CDI, plus a surcharge of 1.49% per year, and payment term of seven years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on January 25, 2029. The funds were used to improve the working capital.

On March 7, 2022, the Company carried out the 6th issue of non-convertible, simple unsecured debentures, in a single series, for public distribution with restricted efforts (CVM 476), with settlement on March 17, 2022, in the amount of R$ 250,000, with remuneration of 100% of CDI, plus a surcharge of 0.70% per year, and payment term of five years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on March 8, 2027. The funds raised were used for the construction, expansion, development and renovation of certain properties indicated by the Company. This operation is linked to the real estate receivables certificates, which were issued with guarantee in the "CRI" debentures, object of a public offering for distribution under CVM Instruction 476.

On June 26, 2022, the Company carried out the 7th issue of non-convertible, simple unsecured debentures, in a single series, for public distribution with restricted efforts (CVM 476), with settlement on June 29, 2022, in the amount of R$ 550,000, with remuneration of 100% of the cumulative variation of the average daily rates of the DI, plus a surcharge of 0.75% per year, and payment term of five years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on June 25, 2029. The funds raised will be used for the construction, expansion, development and renovation of certain properties indicated by the Company. This operation is linked to the real estate receivables certificates, which were issued with guarantee in the "CRI" debentures, object of a public offering for distribution under CVM Instruction 476.

On September 15, 2023, the Company carried out the 8th issue of non-convertible, simple unsecured debentures, in three series, for public distribution with firm placement guarantee, pursuant to CVM Resolutions No. 160 and No. 60, as well as other applicable legal and regulatory provisions, with settlement on September 15, 2023, in the amounts of R$ 350,000 for the 1st series, R$ 150,000 for the 2nd series and R$ 200,000 for the 3rd series, with remuneration of 100% of the cumulative variation of the average daily rates of the DI, plus a surcharge of 0.30% p.a. for the 1st series, 0.65% p.a. for the 2nd series, and 1.10% p.a. for the 3rd series, with payment term of two, four and seven years, respectively. Interest payments will be semi-annual, and principal will be amortized for the 1st series on September 11, 2025, for the 2nd series on September 13, 2027, and for the 3rd series in two equal annual and consecutive installments, the last installment to be paid on September 12, 2030. The funds raised were used for real estate costs and expenses referring to the payment of rentals of certain properties indicated by the Company. This operation is linked to the real estate receivables certificates, which were issued with guarantee in the "CRI" debentures, object of a public offering for distribution under CVM Resolutions 160 and 60.

On April 22, 2024, the Company carried out the 9th issue of non-convertible, simple unsecured debentures, in a single series, for public distribution with restricted efforts (CVM 160), with settlement on May 3, 2024, in the amount of R$ 600,000, with remuneration of 100% of the cumulative variation of the average daily rates of the DI, plus a surcharge of 0.65% per year, and payment term of seven years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on April 22, 2031. The funds were used to strengthen cash.

On April 15, 2025, the Company carried out the 6th issue of non-convertible, simple unsecured debentures, in a single series, for public distribution with restricted efforts (CVM 160), with settlement on April 17, 2025, in the amount of R$ 500,000, with remuneration of 100% of DI, plus a surcharge of 0.60% per year, and payment term of seven years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on April 15, 2032. The funds were used to strengthen cash.

On November 10, 2025, the Company carried out the 6th issue of non-convertible, simple unsecured debentures, in a single series, for public distribution with restricted efforts (CVM 160), with settlement on November 10, 2025, in the amount of R$ 600,000, with remuneration of 100% of DI, plus a surcharge of 0.44% per year, and payment term of seven years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on November 10, 2032. The funds were used to strengthen cash.

The costs incurred on the issues of the Company's debentures (2019 - 3rd and 4th issues, 2022 - 5th, 6th and 7th issues, 2023 - 8th issue, 2024 - 9th issue and 2025 - 10th and 11thissues), including fees, commissions and other costs are classified in the line item of the respective debentures, and will be recognized over the total period of the debt. At June 30, 2026, the amount to be recognized was R$ 20,182 (R$ 21,991 – Dec/2025), and is presented net in debentures balance.

The Company's debentures are conditioned to the compliance with the following covenants:

(i) Net Debt / EBTIDA: cannot exceed 3 times.

The calculation of net debt, the basis for determining the covenants calculation of Company's debentures, considers the balances of borrowings. As described in Note 26,2 (e), the lease obligations are being presented in a separate line item in the Interim Financial Information, and therefore are not included in the net debt calculation.

Covenants are measured quarterly and, at June 30, 2026, the Company was in compliance with such requirements.

The non-compliance with the covenants for two consecutive quarters can be considered as a default event and consequently result in early maturity.

The Group monitors clauses subject to compliance with financial and non-financial covenants, in order to ensure that they are being complied with. At June 30, 2026, the Company was in compliance with these covenants.

(All amounts in thousands of reais unless otherwise stated)

(c) Reconciliation of net debt

The analysis of and the changes in net debt are presented below:

	Parent Company		Consolidated	
Composition and changes in net debt	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
Short-term borrowings	365,266	508,137	365,266	508,137
Long-term borrowings	3,087,383	3,359,618	3,087,383	3,359,618
Total debt	**3,452,649**	**3,867,755**	**3,452,649**	**3,867,755**
(-) Cash and cash equivalents (Note 5)	(322,902)	(296,965)	(536,501)	(509,619)
Net debt	**3,129,747**	**3,570,790**	**2,916,148**	**3,358,136**

	Parent Company		
Changes in net debt	**Borrowings**	**Cash and cash equivalents**	**Net debt**
Net debt at January 1, 2025	**3,204,348**	**(460,292)**	**2,744,056**
Funding	500,000	-	500,000
Accrued interest	222,087	-	222,087
Payment of interest	(195,702)	-	(195,702)
Amortization of principal	(125,000)	-	(125,000)
Transaction cost – net	2,596	-	2,596
Increase in cash and cash equivalents	-	132,453	132,453
Net debt at June 30, 2025	**3,608,329**	**(327,839)**	**3,280,490**
Funding	600,000	-	600,000
Accrued interest	273,468	-	273,468
Payment of interest	(265,481)	-	(265,481)
Amortization of principal	(350,000)	-	(350,000)
Transaction cost – inflows (-)	(5,244)	-	(5,244)
Transaction cost - amortizations	6,683	-	6,683
Decrease in cash and cash equivalents	-	30,874	30,874
Net debt at December 31, 2025	**3,867,755**	**(296,965)**	**3,570,790**
Accrued interest	262,268	-	262,268
Payment of interest	(280,729)	-	(280,729)
Amortization of principal	(400,000)	-	(400,000)
Transaction cost – inflows (-)	(778)	-	(778)
Transaction cost - amortizations	4,133	-	4,133
Increase in cash and cash equivalents	-	(25,937)	(25,937)
Net debt at June 30, 2026	**3,452,649**	**(322,902)**	**3,129,747**

(All amounts in thousands of reais unless otherwise stated)

	Consolidated		
Changes in net debt	**Borrowings**	**Cash and cash equivalents**	**Net debt**
Net debt at January 1, 2025	**3,293,930**	**(528,002)**	**2,765,928**
Funding	590,000	-	590,000
Accrued interest	222,624	-	222,624
Charges on borrowings	5,443	-	5,443
Payment of interest	(197,858)	-	(197,858)
Amortization of principal	(213,869)	-	(213,869)
Transaction cost – net	2,596	-	2,596
Increase in cash and cash equivalents	-	982	982
Net debt at June 30, 2025	**3,702,866**	**(527,020)**	**3,175,846**
Funding	600,000	-	600,000
Accrued interest	273,468	-	273,468
Charges on borrowings	1,957	-	1,957
Payment of interest	(271,975)	-	(271,975)
Amortization of principal	(440,000)	-	(440,000)
Transaction cost – inflows (-)	(5,244)	-	(5,244)
Transaction cost - amortizations	6,683	-	6,683
Increase in cash and cash equivalents	-	17,401	17,401
Net debt at December 31, 2025	**3,867,755**	**(509,619)**	**3,358,136**
Accrued interest	262,268	-	262,268
Payment of interest	(280,729)	-	(280,729)
Amortization of principal	(400,000)	-	(400,000)
Transaction cost – inflows (-)	(778)	-	(778)
Transaction cost - amortizations	4,133	-	4,133
Decrease in cash and cash equivalents	-	(26,882)	(26,882)
Net debt at June 30, 2026	**3,452,649**	**(536,501)**	**2,916,148**

(All amounts in thousands of reais unless otherwise stated)

17. Leases

As a lessee

Right-of-use assets

Breakdown of Parent Company and Consolidated right-of-use assets:

	Parent Company		Consolidated	
Right-of-use assets	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
Operating real estate	3,874,317	3,807,070	3,875,475	3,808,354
Residential real estate	53,371	50,585	53,370	50,807
Distribution centers and administrative properties	511,319	464,181	511,319	469,476
Vehicles	23,933	7,410	23,934	7,411
Total	**4,462,940**	**4,329,246**	**4,464,098**	**4,336,048**

The changes in the Parent Company and Consolidated right-of-use assets are presented below:

	Parent Company				
	Operating real estate	**Residential real estate**	**Distribution/ administrative centers**	**Vehicles**	**Total**
At 01/01/2025	**3,418,181**	**27,357**	**429,704**	**6,325**	**3,881,567**
New agreements	282,521	9,319	831	-	292,671
Remeasurements (i)	390,038	8,494	67,561	3,031	469,124
Termination of agreements	(11,057)	(4,604)	-	-	(15,661)
Depreciation	(442,927)	(3,545)	(52,702)	(820)	(499,994)
At 06/30/2025	**3,636,756**	**37,021**	**445,394**	**8,536**	**4,127,707**
New agreements	288,095	5,025	304	169	293,593
Remeasurements (i)	360,699	13,052	73,673	(437)	446,987
Termination of agreements	(14,650)	(801)	-	-	(15,451)
Depreciation	(463,830)	(3,712)	(55,190)	(858)	(523,590)
At 12/31/2025	**3,807,070**	**50,585**	**464,181**	**7,410**	**4,329,246**
New agreements	272,073	6,434	28,664	13,405	320,576
Remeasurements (i)	283,146	5,109	76,427	3,368	368,050
Termination of agreements	(9,451)	(4,976)	-	-	(14,427)
Depreciation	(478,521)	(3,781)	(57,953)	(250)	(540,505)
At 06/30/2026	**3,874,317**	**53,371**	**511,319**	**23,933**	**4,462,940**

	Consolidated				
	Operating real estate	**Residential real estate**	**Distribution/ administrative centers**	**Vehicles**	**Total**
At 01/01/2025	**3,419,464**	**27,622**	**433,565**	**6,326**	**3,886,977**
New agreements	282,521	9,319	2,345	-	294,185
Remeasurements (i)	390,038	8,498	68,149	3,030	469,715
Termination of agreements	(11,057)	(4,622)	-	-	(15,679)
Depreciation	(442,927)	(3,556)	(53,914)	(820)	(501,217)
At 06/30/2025	**3,638,039**	**37,261**	**450,145**	**8,536**	**4,133,981**
New agreements	288,095	5,025	2,351	169	295,640
Remeasurements (i)	360,699	13,052	73,721	(436)	447,036
Termination of agreements	(14,650)	(816)	(510)	-	(15,976)
Depreciation	(463,829)	(3,715)	(56,231)	(858)	(524,633)
At 12/31/2025	**3,808,354**	**50,807**	**469,476**	**7,411**	**4,336,048**
New agreements	273,471	6,434	28,664	13,405	321,974
Remeasurements (i)	283,144	5,109	76,646	3,368	368,267
Termination of agreements	(9,451)	(4,976)	-	-	(14,427)
Depreciation	(478,760)	(3,781)	(58,483)	(250)	(541,274)
Write-off due to sale of investee	(1,283)	(223)	(4,984)	-	(6,490)
At 06/30/2026	**3,875,475**	**53,370**	**511,319**	**23,934**	**4,464,098**

(All amounts in thousands of reais unless otherwise stated)

(i) The Company remeasures the right-of-use assets in order to reflect changes in future payments; changes in terms initially determined for the implementation of NBC TG 06 (R3) / IFRS 16 - Leases and contracts recognized as operating leases (NBC TG 06 (R3) / IAS 17 - Leases), initially determined as short-term contracts.

Lease liabilities

The changes in the Parent Company and Consolidated lease liabilities are as follows:

	Parent Company	Consolidated
At 01/01/2025	**4,418,993**	**4,424,537**
New agreements	292,671	294,185
Remeasurements (i)	469,123	469,715
Termination of agreements	(34,435)	(34,454)
Interest	231,691	232,000
Payments / compensations	(660,042)	(661,479)
At 06/30/2025	**4,718,001**	**4,724,504**
New agreements	293,593	295,640
Remeasurements (i)	446,988	447,036
Termination of agreements	(8,639)	(9,163)
Interest	246,358	246,616
Payments / compensations	(737,070)	(738,321)
At 12/31/2025	**4,959,231**	**4,966,312**
New agreements	320,576	321,982
Remeasurements (i)	368,052	368,268
Termination of agreements	(17,613)	(17,613)
Interest	268,275	268,582
Payments / compensations	(759,347)	(760,323)
Write-off due to sale of investee	-	(6,822)
At 06/30/2026	**5,139,174**	**5,140,386**

(i) The Company remeasures the lease liabilities in order to reflect changes in future payments; changes in terms initially determined for the implementation of NBC TG 06 (R3) / IFRS 16 - Leases and contracts recognized as operating leases (NBC TG 06 (R3) / IAS 17 - Leases).

The maturities of lease liabilities are classified according to the following schedule:

	Parent Company		Consolidated	
Analysis of maturities - Lease liabilities	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
Less than 1 year	1,025,101	1,019,344	1,025,313	1,021,147
Current liabilities	**1,025,101**	**1,019,344**	**1,025,313**	**1,021,147**
1 to 5 years	2,979,722	2,971,403	2,980,722	2,976,681
Over 5 years	1,134,351	968,484	1,134,351	968,484
Non-current	**4,114,073**	**3,939,887**	**4,115,073**	**3,945,165**
Total	**5,139,174**	**4,959,231**	**5,140,386**	**4,966,312**

Future payments to be made to the lessor may give the Group the right to be credited with PIS and COFINS. Therefore, the recorded amount of the right-of-use asset against the lease liability already includes potential future credit.

The potential right to PIS and COFINS recoverable embedded in future lease payments is presented below:

Future considerations	Parent Company	Potential PIS / COFINS (9.25%)
Less than 1 year	1,039,843	96,185
1 to 2 years	902,300	83,463
2 to 3 years	740,971	68,540
3 to 4 years	598,336	55,346
4 to 5 years	475,618	43,995
Over 5 years	1,287,421	119,086
Total	**5,044,489**	**466,615**

(All amounts in thousands of reais unless otherwise stated)

The right to use PIS and COFINS credits comprises only contracts whose lessor is a legal entity. The Company has lease contracts for both lessors, corporate and individual.

In compliance with CVM Circular Letter 02/2019 and NBC TG 06 (R3) / IFRS 16, justified by the fact that the Group has not applied the methodology of nominal flows due to the prohibition imposed by NBC TG 06 (R3) of future inflation projection and in order to provide additional information to the users of the Group's financial statements, the analysis of contract maturities and installments not yet discounted at June 30, 2026 is presented below:

	Parent Company			Consolidated		
Year	**Amounts of installments not yet discounted**	**Estimated interest (future) (i)**	**Net present value**	**Amounts of installments not yet discounted**	**Estimated interest (future) (i)**	**Net present value**
2026	777,890	(266,479)	511,411	778,102	(266,479)	511,623
2027	1,464,258	(461,603)	1,002,655	1,464,258	(461,603)	1,002,655
2028	1,205,787	(370,647)	835,140	1,206,787	(370,647)	836,140
2029	952,484	(291,069)	661,415	952,484	(291,069)	661,415
2030	774,172	(225,339)	548,833	774,172	(225,339)	548,833
2031 and thereafter	2,045,824	(466,104)	1,579,720	2,045,824	(466,104)	1,579,720
Total	**7,220,415**	**(2,081,241)**	**5,139,174**	**7,221,627**	**(2,081,241)**	**5,140,386**

(i) The present value of the leases payable was calculated considering the projection of future fixed payments, discounted at the rate of 15.31% p.a. (15.77% p.a. – Dec/25), which was built from the basic interest rate released by the Central Bank of Brazil (BACEN).

Amount recognized in the statement of income

	Parent Company		Consolidated	
Amount recognized in the statement of income	**Jun/26**	**Jun/25**	**Jun/26**	**Jun/25**
Depreciation of right-of-use assets	540,505	499,994	541,274	498,771
Interest on lease liabilities	268,275	231,691	268,582	232,000
Adjustment for lease write-off (contracts terminated)	(1,890)	(13,180)	(1,890)	(13,180)
Variable payments not included in the measurement of lease liabilities	33,246	30,524	33,246	31,231
Revenue on subleases of right-of-use assets	(2,575)	(2,166)	(2,575)	(2,166)
Expenses related to short-term and/or low-value leases	8,564	13,805	8,564	13,805

(i) Payment of variable leases based on sales

Some operating real estate leases contain variable lease payments based on a percentage of 2% to 12% of the sales made during the period in the leased operating real estate. These payment conditions are common for stores in the country where the Group operates. Variable lease payments for the period ended June 30, 2026 amounted to R$ 3,046 (R$ 7,651 in Dec/25) for Parent Company and consolidated accounts.

(ii) Leases fitting into exceptions and practical expedients

The lease agreements identified and that fall within the scope of exemption mainly refer to lease of printers, forklifts, scales, power generators, electron aligners and photovoltaic plates.

The Group also leases equipment with contracts of up to one year. These leases are short-term and/or low-value leases. The Group opted not to recognize the right-of-use assets and the lease liabilities of such items.

(All amounts in thousands of reais unless otherwise stated)

As a lessor

The Group subleases some of the properties to third parties. The Group has classified these leases as operating leases because they do not transfer substantially all the risks and rewards of ownership of assets.

The table below presents an analysis of maturities of lease payments, showing undiscounted lease payments to be received after the reporting date:

	Parent Company and Consolidated	
Undiscounted lease payments	**Jun/26**	**Dec/25**
Less than 1 year	1,439	1,401
1 to 2 years	1,439	1,438
2 to 3 years	1,439	1,438
3 to 4 years	1,058	1,375
4 to 5 years	29	61
Over 5 years	124	127
Total	**5,528**	**5,840**

(All amounts in thousands of reais unless otherwise stated)

18.Provision for contingencies and judicial deposits

Breakdown of balances and changes in provisions

At June 30, 2026, the Group had the following provisions and corresponding judicial deposits relating to legal proceedings:

	Parent Company		Consolidated	
Judicial deposit items	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
Labor and social security	148,932	153,897	148,932	154,359
Tax [i]	18,278	21,675	18,278	134,768
Civil	20,087	17,946	20,087	17,946
Total	**187,297**	**193,518**	**187,297**	**307,073**
Current liabilities	42,116	58,220	42,116	58,220
Non-current liabilities	145,181	135,298	145,181	248,853

(i) One of the Company's subsidiaries is a party to lawsuits challenging the payment of the differences in ICMS rates in certain states, recording judicial deposits for the amounts in dispute. In this context, up to the first quarter of 2022, the subsidiary adopted the practice of recording a provision for the judicial deposits. Considering the lawsuits with final and unappealable decisions favorable to the subsidiary, occurred during the first quarter of 2022, and the withdrawal of the deposits, it was decided, after the assessment of the external advisors, that the provision for the deposited amounts would be reversed in March 2022. After the decision of the Federal Supreme Court (STF) on November 29, 2023, the subsidiary started to record a provision referring to the lawsuits challenging the payment of the ICMS- DIFAL in certain states, considering the judicial deposits made between April 2022 and December 2023.

On October 21, 2025, the Federal Supreme Court (STF), by majority vote, revised its previous decision and introduced the modulation of effects, ruling that taxpayers who filed lawsuits before November 29, 2023, and did not collect the tax cannot be charged the ICMS Rate Differential ("DIFAL") related to fiscal year 2022. In light of this decision, the Company reassessed the associated risks and reversed the provision previously recognized for this period, in the amount of R$ 70,098 (comprising R$ 55,760 in principal and R$ 14,338 in monetary adjustment).

Changes in the provision are as follows:

Changes in the contingencies	**Parent Company**	**Consolidated**
At January 1, 2025	**168,509**	**363,888**
Additions of new lawsuits and review of estimate	62,816	63,236
Write-offs for payments	(17,617)	(17,617)
Constitution/(Reversals) due to changes in lawsuits	(34,296)	(51,058)
At June 30, 2025	**179,412**	**358,449**
Additions of new lawsuits and review of estimate	100,000	101,342
Write-offs for payments	(52,108)	(52,108)
Constitution/(Reversals) due to changes in lawsuits	(15,363)	(93,782)
Monetary adjustment	(18,423)	(6,828)
At December 31, 2025	**193,518**	**307,073**
Additions of new lawsuits and review of estimate	73,390	73,390
Write-offs for payments	(53,414)	(53,414)
Constitution/(Reversals) due to changes in lawsuits	(24,716)	(24,716)
Transfer to liabilities held for sale	-	(113,555)
Monetary adjustment	(1,481)	(1,481)
At June 30, 2026	**187,297**	**187,297**

The provision for legal claims took into consideration the best estimate of the amounts involved, for the cases in which the likelihood of loss is estimated as probable, remaining a portion of these claims guaranteed by pledged assets.

(All amounts in thousands of reais unless otherwise stated)

Possible losses

At June 30, 2026, the Group has tax lawsuits related to fines applied by the relevant administrative authorities, tax rate difference in interstate transfers and tax enforcements, as well as civil lawsuits due to indemnity claims for losses and pain and suffering arising from consumer relations, and sundry labor claims, involving possible loss as assessed by Management and its legal advisors in the amount of R$ 964,868 for the Parent Company and R$ 1,229,509 for the Consolidated (R$ 938,114 and R$ 1,003,604, respectively, in Dec/2025), of which R$ 886,913 for the Parent Company and R$ 1,151,554 for the Consolidated refer to tax lawsuits (R$ 820,040 for the Parent Company and R$ 885,530 for the Consolidated – Dec/2025), the total of R$ 42,537 refers to labor claims for the Parent Company and Consolidated (R$ 35,249 – Dec/2025) and the amount of R$ 35,418 for both the Parent Company and Consolidated corresponds to civil lawsuits (R$ 82,825 – Dec/2025).

Judicial deposits

At June 30, 2026, the Group had the following judicial deposit amounts, for which no corresponding provision had been set up:

	Parent Company		Consolidated	
Analysis of judicial deposits	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
Labor and social security	12,081	10,529	12,117	10,669
Tax	49,805	49,937	49,805	284,887
Civil	6,758	5,730	6,758	5,763
Total	**68,644**	**66,196**	**68,680**	**301,319**
Current assets	3,782	4,970	3,782	4,970
Non-current assets	64,862	61,226	64,898	296,349

Labor contingencies

Most labor claims relate to lawsuits filed by former employees questioning the payment of unpaid overtime and health hazard premium. The Group is also involved in proceedings arising from Raia S.A., as well as from Drogaria Onofre Ltda., which were filed by former employees of service providers claiming to have employment relationships directly with the Group, or in which the Group received a joint enforcement order for the payment of the labor rights claimed. There are also proceedings filed by professional unions for the payment of union dues, under the dispute regarding the legitimacy of the territorial base.

Tax contingencies

These represent administrative fines, tax rate differences on interstate transfers and tax collection proceedings.

Civil contingencies

The Group is a defendant in lawsuits regarding usual and unique matters arising in the course of its business, most of which seek indemnification for property damage and pain and suffering from consumption relations.

Guarantees for lawsuits

The following items of fixed assets were given as guarantees for tax, social security and labor proceedings:

	Parent Company / Consolidated	
Guarantees for lawsuits	**Jun/26**	**Dec/25**
Machinery and equipment	85	85
Total guarantees for lawsuits	**85**	**85**

(All amounts in thousands of reais unless otherwise stated)

19.Income tax and social contribution

19.1. Breakdown of current income tax and social contribution and effective rate

Effective income tax and social contribution items	Parent Company Jun/26	Parent Company Jun/25	Consolidated Jun/26	Consolidated Jun/25 Restated
Profit before income tax and social contribution	670,678	609,976	657,139	542,370
Interest on capital and additional interest on capital proposed	(304,900)	(249,900)	(304,900)	(249,900)
Taxable profit	**365,778**	**360,076**	**352,237**	**292,470**
Combined tax rate (25% for income tax and 9% for social contribution)	34.00%	34.00%	34.00%	34.00%
Theoretical tax expense	**(124,365)**	**(122,426)**	**(119,761)**	**(99,440)**
Permanent additions and/or exclusions	(15,314)	(11,082)	(17,731)	(11,070)
Equity in the results of subsidiaries	8,828	26,622	221	(206)
Investment grant(i)	19,482	9,495	19,482	9,495
Tax incentives — Lei do Bem	15,677	9,707	15,677	9,707
Tax incentives - Other incentives	10,154	11,016	10,154	11,016
Other	(1,645)	4,663	(1,645)	4,663
Result of current income tax and social contribution	**(86,927)**	**(104,379)**	**(91,663)**	**(108,305)**
Result of deferred income tax and social contribution	**(256)**	**32,374**	**(1,940)**	**32,470**
Income tax and social contribution expense	**(86,614)**	**(72,005)**	**(93,603)**	**(75,835)**
Effective tax rate	**12.91%**	**11.80%**	**14.24%**	**8.71%**

(i) Change in tax position of the treatment of the investment grant due to the new STJ precedent in June 2025, which recognized the undue inclusion of the presumed ICMS credit in the IRPJ and CSLL calculation basis, even after the new legislation came into force, as it constitutes a violation of the federative pact.

19.2. Deferred income tax and social contribution are comprised as follows:

Deferred income tax and social contribution assets amounting to R$ 507,160 in Jun/26 (R$ 507,494 – Dec/25) for the Parent Company and R$ 558,172 in Jun/26 (R$ 660,839 – Dec/25) for the Consolidated accounts arose from temporarily non-deductible expenses that may be carried forward indefinitely, with estimated realization as disclosed in item 19.3 below.

Deferred income tax and social contribution liabilities amounting to R$ 302,505 in June/26 (R$ 302,614 – Dec/25) for the Parent Company and R$ 302,506 in Jun/26 (R$ 303,352 – Dec/25) for the Consolidated accounts relate to tax charges on the remaining balances of: (i) the revaluation reserve; (ii) PPA (Purchase Price Allocation); and (iii) gain on bargain purchase.

(All amounts in thousands of reais unless otherwise stated)

In the periods ended June 30, 2026 and 2025, deferred income tax and social contribution were as follows:

	Balance sheet				Statement of income			
	Parent Company		Consolidated		Parent Company		Consolidated	
Temporary differences	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**	**Jun/26**	**Jun/25**	**Jun/26**	**Jun/25** Restated
Revaluation at fair value of land and buildings[i]	(6,398)	(6,429)	(6,398)	(7,167)	-	-	-	-
Amortization of the goodwill on future profitability [ii]	(243,009)	(243,008)	(243,009)	(243,008)	1	1	1	1
Non-deductible intangible assets	(53,099)	(53,177)	(53,099)	(53,177)	(78)	(78)	(78)	(78)
Tax losses to be offset against future taxable profits	-	-	-	153,345	-	-	1,727	-
Adjustment to present value	9,556	12,576	9,556	12,576	3,021	1,561	3,021	1,561
Provision for inventory losses	25,872	30,939	25,872	30,939	5,068	(9,590)	5,068	(9,590)
Provision for sundry obligations	103,060	93,525	103,060	93,525	(9,535)	(12,760)	(9,535)	(12,760)
Provision for employee profit sharing	28,568	41,123	28,568	41,123	12,555	13,653	12,555	13,653
Provision for contingencies	80,020	73,856	80,020	73,856	(6,164)	(8,284)	(6,164)	(8,284)
Expected credit losses	3,500	1,892	3,500	1,892	(1,608)	(1,221)	(1,608)	(1,221)
Lease (depreciation - asset)	2,859,509	2,585,167	2,859,509	2,585,167	(274,342)	(248,225)	(274,342)	(242,165)
Lease (consideration - liability)	(2,627,538)	(2,368,298)	(2,627,538)	(2,368,298)	259,240	229,465	259,240	223,405
Fair value adjustment on investment – sale of 4Bio	(20)	-	(20)	-	20	-	20	-
Other adjustments	24,634	36,714	75,645	36,714	12,078	3,104	12,035	3,008
Deferred income tax and social contribution expense					**256**	**(32,374)**	**1,940**	**(32,470)**
Deferred tax assets, net	**204,655**	**204,880**	**255,666**	**357,487**				
Deferred tax liabilities, net	**-**	**-**	**-**	**-**				
Reflected in the balance sheet as follows:								
Deferred tax assets	507,160	507,494	558,172	660,839				
Deferred tax liabilities	(302,505)	(302,614)	(302,506)	(303,352)				
Deferred tax assets, net – Parent Company	**204,655**	**204,880**	**204,655**	**204,880**				
Deferred tax liabilities, net	**-**	**-**	**-**	**-**				
Deferred tax assets – Subsidiaries	**-**	**-**	**51,011**	**152,607**				
Reconciliation of deferred tax assets (liabilities), net								
Balance at the beginning of the year	204,880	141,278	357,487	298,405				
Expense recognized in the statement of income	(256)	63,538	(1,940)	58,949				
Asset held for sale	-	-	(107,592)	-				
Asset acquisition of control - Stix	-	-	7,681	-				
Realization of deferred tax recognized in equity	31	64	30	133				
Balance at the end of the period	**204,655**	**204,880**	**255,666**	**357,487**				

Voltar

(All amounts in thousands of reais unless otherwise stated)

19.3. Estimated recovery of income tax and social contribution credits

The projections of future taxable profits are based on estimates relating to the Group's performance, the behavior of the market in which the Group operates and certain economic aspects, among other factors. Actual amounts may differ from these estimates. According to projections, the tax credit will be recovered according to the following schedule:

	Parent Company		Consolidated	
Recovery forecast	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
2026	248,366	259,432	299,377	304,446
2027	75,644	72,111	75,644	99,194
2028	56,604	55,060	56,604	82,143
2029	81,095	77,835	81,095	104,918
2030 and thereafter	45,451	43,056	45,452	70,138
Total	**507,160**	**507,494**	**558,172**	**660,839**
Deferred tax assets on temporary differences, recorded net in liabilities	507,160	507,494	558,172	507,494
Deferred tax assets on tax losses in subsidiaries	-	-	-	153,345

19.4. Uncertainties over the IRPJ and CSLL tax treatment

The Company has four discussions in the administrative stage with the Brazilian Federal Revenue referring to the disallowance for tax amortization of goodwill arising from acquisitions of companies in the amount of R$ 25,023, which, according to internal and external assessment of legal advisors, will probably be accepted in decisions of higher courts (probability of acceptance higher than 50%); for this reason, the Company did not record any IRPJ and CSLL liabilities in connection with these proceedings. The Company also has an uncertain position related to the treatment of investment subsidies, as disclosed in note 19.1(i).

20. Earnings per share

Basic earnings per share are calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of common shares outstanding during the period. Diluted earnings per share are calculated by adjusting the weighted average number of common shares outstanding to assume conversion of all potential common diluted shares.

The following table presents profit and share information used for calculating basic and diluted earnings per share:

	Parent Company / Consolidated	
Earnings per share items	**Jun/26**	**Jun/25**
Basic		
Profit for the period	583,495	537,971
Weighted average number of common shares	1,647,610	1,646,763
Basic earnings per share - R$	**0.35415**	**0.32668**
Diluted		
Profit for the period	583,495	537,971
Weighted average number of common shares adjusted for dilution effect	1,675,760	1,655,537
Diluted earnings per share - R$	**0.34820**	**0.32495**

(All amounts in thousands of reais unless otherwise stated)

21. Equity

(a) Share capital

At June 30, 2026, the fully paid-up capital amounted to R$ 4,750,000 (R$ 4,750,000 – Dec/25), represented by 1,752,367,344 book-entry registered common shares, with no par value, of which 1,314,310,978 were outstanding common shares (1,315,246,622 common shares – Dec/25).

Pursuant to the Company's bylaws, it is authorized to increase its capital up to the limit of 2,000,000,000 common shares, subject to the approval of the Board of Directors.

At June 30, 2026, the Company's ownership structure was as follows:

	Number of shares		Interest (%)	
Ownership interest	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
Controlling shareholders	434,225,259	432,017,272	24.78	24.65
Shares outstanding	1,314,310,978	1,315,246,622	75.00	75.06
Treasury shares	3,831,107	5,103,450	0.22	0.29
Total	**1,752,367,344**	**1,752,367,344**	**100.00**	**100.00**

The ownership interest of the controlling shareholders is represented by the families Pipponzi, Pires Oliveira Dias and Galvão.

The change in the number of outstanding shares of the Company is as follows:

Changes	Shares outstanding
At January 1, 2025	1,290,335,615
(Purchase)/sale of restricted shares, net	24,911,007
At December 31, 2025	**1,315,246,622**
(Purchase)/sale of restricted shares, net	(935,644)
At June 30, 2026	**1,314,310,978**

At June 30, 2026, the Company's common shares were quoted at R$ 16.81 (closing quote) (R$ 23.45 – Dec/25).

(b) Treasury shares

The changes in treasury shares in the period ended June 30, 2026 are summarized below:

	Parent Company	
Changes in treasury shares	**Number of shares**	**Amount of shares**
At January 1, 2025	**6,012,572**	**124,991**
Shares delivered to executives related to the 3rd tranche of the 2021 grant, 2nd tranche of the 2022 grant, 1st tranche of the 2023 grant, and Performance Share 2020	(956,355)	(19,810)
Shares delivered to executives related to the 3rd tranche of the 2021 grant, 2nd tranche of the 2022 grant, and 1st tranche of the 2023 grant of the subsidiaries	(52,834)	(1,099)
Bonus shares	100,067	-
At December 31, 2025	**5,103,450**	**104,082**
Shares delivered to executives related to the 3rd tranche of the 2021 grant, 2nd tranche of the 2022 grant, 1st tranche of the 2023 grant, and Performance Share 2020	(1,204,337)	(24,316)
Shares delivered to executives related to the 3rd tranche of the 2021 grant, 2nd tranche of the 2022 grant, and 1st tranche of the 2023 grant of the subsidiaries	(68,006)	(1,387)
At June 30, 2026	**3,831,107**	**78,379**

At June 30, 2026, the market value of the treasury shares, having as reference the quotation of R$ 16.81 per share (R$ 23.45 - Dec/25), corresponds to R$ 64,401 (R$ 119,676 - Dec/25).

(c) Restricted share plan

Long-Term Incentive Program

Since March 2014, the Company offers its officers the Long-Term Incentive Program with Restricted Shares (the "Restricted Share Plan"), which aims to offer an opportunity to receive variable compensation provided that the officer remains for a predetermined period in the Company.

The maximum number of shares that may be delivered as a result of the exercise of the Plan is limited to 3% of the Company's Capital during the entire term of the Plan. The reference price per restricted share, for the purpose of determining the target amount that will be granted to each Beneficiary, will be equivalent to the average share price on B3 (weighted by the volume of trades) in the last thirty trading sessions preceding the grant.

As stated in the Restricted Share Plan, a portion of their annual variable compensation (profit-sharing) will be paid to the officer in cash and the remaining balance shall be paid only in Company shares ("incentive stock").

If the officer decides to use a portion or the total amount of the variable compensation paid in cash to buy Company shares ("own shares") on the stock exchange, the Company will offer the officer an equal number of shares purchased on the stock exchange.

At its discretion, the Company may grant to this officer more Company shares, using as reference the number of own shares acquired by the officer on the stock exchange.

The shares offered to the officer through the Restricted Share Plan may not be sold, assigned or transferred to third parties for a period of four years from the date of the grant. Every year, from the second, third and fourth anniversary of the grant date, the officers will acquire the right to receive a third of their restricted stock. The portion not exercised within the established terms and conditions will be automatically considered extinguished 7 years after the respective grant date. The fair value of the plan was R$ 156,710 at June 30, 2026 (R$ 172,488 - Dec/2025). The plans are measured at fair value on the grant date and are subsequently recognized in profit or loss on a pro rata basis until the plan vests. The exercise price of the options is equal to the market price of the shares on the grant date.

Performance shares

At a meeting of the Board of Directors on October 22, 2020, the granting of restricted shares was approved under the terms of the Restricted Share Granting Plan - Performance Shares (“Plan”), approved at the Extraordinary General Meeting of the Company held on September 15, 2020.

The purpose of the Plan is: (a) to foster the expansion, success and fulfillment of the corporate purposes of the Company and the companies under its control; (b) to align the interests of Beneficiaries with the interests of shareholders; and (c) to encourage Beneficiaries to stay in the Company or companies under its control. The Plan will be managed by the Board of Directors, and may have an advisory committee created or appointed by the Board of Directors to advise it in this respect. Beneficiaries will be chosen and elected by the Board of Directors at each new grant.

The maximum number of shares that may be delivered as a result of exercising the Plan is limited to 2% of the Company's Capital on the date of approval of the Plan. The reference price per restricted share, for the purpose of determining the target amount that will be granted to each Beneficiary will be equivalent to the average share price on B3 (weighted by the volume of trades) in the ninety trading sessions prior to January 1 of the year in which the grant occurs.

The definitive transfer of the Restricted Shares will be subject to the fulfillment of a four-year vesting period from the grant date and, at the end of the vesting period, the participant must be linked to the Company so that the grants are not canceled. Restricted Shares that have not yet completed the vesting period will become due and will be transferred to the holders, their estate or heirs in the event of death, permanent disability or retirement. The Plan provides that the liquidation must occur through the transfer of shares, however, in the event that the Company does not have treasury shares at the time of liquidation and / or upon inability to acquire shares on the market, the Board of Directors may choose to settle the delivery of the Restricted Shares in cash.

(All amounts in thousands of reais unless otherwise stated)

Changes in restricted shares

The changes in restricted shares are summarized below:

	Jun/26		Dec/25	
Changes in restricted shares	**Shares**	**Amount**	**Shares**	**Amount**
Opening balance at January 1	9,629,847	89,704	7,834,296	90,237
Granted shares for the period / year	1,287,728	17,010	2,704,673	27,880
Value of the shares at the delivery date	(1,272,343)	(26,572)	(909,122)	(28,413)
Closing balance	**9,645,232**	**80,142**	**9,629,847**	**89,704**

Position of the restricted share plan

Below is a breakdown of the assumptions that govern each grant plan:

Grants	Grant date	Number of shares granted(i)	Date on which they will become exercisable	Period of restriction to share transfer	Fair value of shares on grant date(i)
Long-Term Incentive Program					
2023 - 3rd tranche(i)	3/01/2023	566,160	2/28/2027	2/28/2026	R$ 23.90
2024 - 2nd tranche	3/01/2024	492,339	2/28/2027	2/28/2026	R$ 26.76
2024 - 3rd tranche	3/01/2024	492,243	2/28/2028	2/28/2027	R$ 26.76
2025 - 1st tranche	3/01/2025	628,650	2/28/2027	2/28/2026	R$ 22.15
2025 - 2nd tranche	3/01/2025	628,650	2/28/2028	2/28/2027	R$ 22.15
2025 - 3rd tranche	3/01/2025	628,753	2/28/2029	2/28/2029	R$ 22.15
2026 - 1st tranche	3/01/2026	400,510	2/28/2028	2/28/2028	R$ 23.38
2026 - 2nd tranche	3/01/2026	400,510	2/28/2029	2/28/2029	R$ 23.38
2026 - 3rd tranche	3/01/2026	400,588	2/28/2030	2/28/2030	R$ 23.38
Performance shares					
2021 - 1st tranche	1/01/2021	303,887	2/01/2025	1/01/2028	R$ 22.82
2022 - 1st tranche	1/01/2022	386,840	2/01/2026	1/01/2027	R$ 22.44
2023 - 1st tranche	1/01/2023	441,388	2/01/2027	1/01/2028	R$ 22.18
2024 - 1st tranche	1/01/2024	402,056	2/01/2028	1/01/2029	R$ 26.86
2025 - 1st tranche	1/01/2025	422,406	2/01/2029	1/01/2030	R$ 24.79
2026 - 1st tranche	1/01/2026	604,302	2/01/2030	1/01/2031	R$ 17.08

(i) After the application of the stock split effect, approved at the EGM held on September 15, 2020 and, on April 10, 2023 as a bonus, 1 (one) new share for every 25 (twenty-five) shares issued by the Company that were outstanding.

(All amounts in thousands of reais unless otherwise stated)

22.Net sales revenue

Breakdown of net revenue	Parent Company			
	2nd Quarter/26	Jun/26	2nd Quarter/25	Jun/25
			Restated	Restated
Sales revenue	12,680,821	24,583,613	10,724,220	20,606,757
Service revenue	24,859	47,855	22,394	40,002
Gross sales revenue	**12,705,680**	**24,631,468**	**10,746,614**	**20,646,759**
Taxes on sales	(1,449,152)	(2,612,186)	(523,180)	(1,017,458)
Returns, rebates and other	(256,436)	(496,714)	(198,904)	(373,756)
Net sales revenue	**11,000,092**	**21,522,568**	**10,024,530**	**19,255,545**

Breakdown of net revenue	Consolidated			
	2nd Quarter/26	Jun/26	2nd Quarter/25	Jun/25
			Restated	Restated
Sales revenue	12,689,604	24,600,192	10,730,730	20,618,356
Service revenue	88,140	157,073	73,196	133,437
Gross sales revenue	**12,777,744**	**24,757,265**	**10,803,926**	**20,751,793**
Taxes on sales	(1,458,897)	(2,629,534)	(530,376)	(1,030,406)
Returns, rebates and other	(256,449)	(496,743)	(198,927)	(373,800)
Net sales revenue	**11,062,398**	**21,630,988**	**10,074,623**	**19,347,587**

(All amounts in thousands of reais unless otherwise stated)

23.Information on the nature of expenses recognized in the statement of income

The Group presented its statement of income using a classification based on the function of expenses. Information on the nature of these expenses is recorded in the statement of income as follows:

	Parent Company			
Nature of expenses	**2nd Quarter/26**	**Jun/26**	**2nd Quarter/25**	**Jun/25**
			Restated	Restated
Costs of inventories sold (Note 8)	(7,338,086)	(14,491,067)	(6,913,966)	(13,342,611)
Personnel expenses	(1,570,670)	(3,081,415)	(1,324,145)	(2,590,263)
Occupancy expenses (i)	(132,106)	(261,274)	(113,816)	(222,796)
Depreciation and amortization (ii)	(528,697)	(1,049,704)	(486,098)	(965,936)
Service provider expenses	(77,340)	(148,133)	(56,005)	(116,713)
Expenses on card operator fees	(186,371)	(366,982)	(162,783)	(312,574)
Others	(330,879)	(637,873)	(269,190)	(547,238)
Total	**(10,164,149)**	**(20,036,448)**	**(9,326,003)**	**(18,098,131)**

Classified in the statement of income as:

Function of expenses	**2nd Quarter/26**	**Jun/26**	**2nd Quarter/25**	**Jun/25**
Costs of sales and services	(7,336,087)	(14,487,494)	(6,913,592)	(13,341,811)
Selling	(2,459,651)	(4,823,267)	(2,069,737)	(4,063,312)
General and administrative	(368,411)	(725,687)	(342,674)	(693,008)
Total	**(10,164,149)**	**(20,036,448)**	**(9,326,003)**	**(18,098,131)**

	Consolidated			
Nature of expenses	**2nd Quarter/26**	**Jun/26**	**2nd Quarter/25**	**Jun/25**
			Restated	Restated
Costs of inventories sold (Note 8)	(7,344,629)	(14,503,444)	(6,919,796)	(13,353,244)
Personnel expenses	(1,589,530)	(3,118,700)	(1,343,011)	(2,625,826)
Occupancy expenses (i)	(130,674)	(258,881)	(113,214)	(221,224)
Depreciation and amortization (ii)	(532,515)	(1,057,284)	(488,808)	(971,294)
Service provider expenses	(99,980)	(188,670)	(77,019)	(157,390)
Expenses on card operator fees	(186,568)	(367,337)	(162,935)	(312,866)
Others	(333,902)	(642,940)	(271,535)	(552,861)
Total	**(10,217,798)**	**(20,137,256)**	**(9,376,318)**	**(18,194,705)**

Classified in the statement of income as:

Function of expenses	**2nd Quarter/26**	**Jun/26**	**2nd Quarter/25**	**Jun/25**
Costs of sales and services	(7,364,668)	(14,538,958)	(6,938,580)	(13,389,496)
Selling	(2,465,559)	(4,835,060)	(2,075,835)	(4,075,127)
General and administrative	(387,571)	(763,238)	(361,903)	(730,082)
Total	**(10,217,798)**	**(20,137,256)**	**(9,376,318)**	**(18,194,705)**

(i) These refer to expenses on property rental, condominium fees, electricity, water, communication and municipal real estate tax (IPTU).

(ii) Depreciation and amortization totaled R$ 1,049,704 in the six-month period of 2026 (R$ 965,936 - Jun/25) for the Parent Company, of which R$ 897,422 (R$ 824,173 - Jun/25) refer to the Sales area and R$ 152,282 (R$ 141,763 - Jun/25) to the Administrative area, and totaled R$ 1,057,284 (R$ 974,703 - Jun/25) for the Consolidated accounts, of which R$ 897,422 (R$ 825,179 - Jun/25) refer to the Sales area and R$ 159,862 (R$ 149,524 - Jun/25) to the Administrative area. These amounts are net of PIS and COFINS credits on the lease right of use, which allowed a reduction of expenses in the amount of R$ 32,806 (R$ 27,326 – Jun/25).

(All amounts in thousands of reais unless otherwise stated)

24.Other operating income or expenses, net

At June 30, 2026, other operating income/(expenses) totaled (R$ 186,186) (R$ 10,987 - June/25) for the Parent company and (R$ 185,808) (R$ 6,953 - June/25) for the Consolidated accounts. These amounts comprise non-recurring expenses and revenues, as presented below:

Nature of income / (expenses)	Parent Company 2nd Quarter/26	Jun/26	2nd Quarter/25 Restated	Jun/25 Restated
Discontinued operation 4Bio [(i)]	(6,657)	(202,796)	-	-
Gain on the acquisition of subsidiary – Stix [(ii)]	19,568	19,568	-	-
Corporate restructuring	-	-	-	(25,640)
Social investment	(2,585)	(5,509)	(2,862)	(6,101)
Donations	(2,459)	(3,643)	(8,306)	(8,669)
Write-off of fixed assets and intangible assets	(6,210)	(5,871)	2,021	558
Refund of ICMS on losses from prior periods	-	-	-	63,842
Tax refund for previous periods (ICMS / ICMS-ST / PIS and COFINS	9,705	14,908	2,001	1,348
Excess losses on unsuitable products	-	-	-	(36,575)
Non-recurring reversals of provisions [(iii)]	13,680	13,680	-	-
Other tax income/expenses	(2,926)	(3,114)	250	250
Other	(12,890)	(13,409)	-	-
Total	**9,226**	**(186,186)**	**(6,896)**	**(10,987)**

(i) As explained in Note 30.1
(ii) As explained in Note 10.1
(iii) Reversal of the provision for contingent consideration payable to the former shareholders of ZTO Tecnologia e Serviços de Informação na Internet Ltda. ("Manipulação Raia Drogasil") for not achieving the goals established in the purchase and sale agreement.

Nature of income / (expenses)	Consolidated 2nd Quarter/26	Jun/26	2nd Quarter/25 Restated	Jun/25 Restated
Discontinued operation 4Bio [(i)]	(6,657)	(202,796)	-	-
Gain on the acquisition of subsidiary – Stix [(ii)]	19,568	19,568	-	-
Corporate restructuring	-	-	-	(25,640)
Social investment	(2,585)	(5,509)	(2,862)	(6,101)
Donations	(2,459)	(3,643)	(8,306)	(8,669)
Write-off of fixed assets and intangible assets	(6,211)	(5,871)	2,021	558
Refund of ICMS on losses from prior periods	-	-	-	63,842
Tax refund for previous periods (ICMS / ICMS-ST / PIS and COFINS	9,705	14,908	2,001	1,348
Excess losses on unsuitable products	-	-	-	(36,575)
Non-recurring reversals of provisions [(iii)]	13,680	13,680	-	-
Other tax income/expenses	(2,926)	(3,114)	250	250
Other	(12,497)	(13,031)	5,177	4,034
Total	**9,618**	**(185,808)**	**(1,719)**	**(6,953)**

(All amounts in thousands of reais unless otherwise stated)

25. Finance income (costs)

	Parent Company			
Finance income	**2nd Quarter/26**	**Jun/26**	**2nd Quarter/25**	**Jun/25**
			Restated	Restated
Present value adjustment	118,526	245,330	92,930	171,463
Short-term investment yields	1,231	2,691	230	4,645
Monetary variations	16,603	31,902	2,029	3,504
Discounts obtained	1,190	1,289	417	758
Other income	2,159	2,160	-	-
Total finance income	**139,709**	**283,372**	**95,606**	**180,370**
Finance costs	**2nd Quarter/26**	**Jun/26**	**2nd Quarter/25**	**Jun/25**
			Restated	Restated
Present value adjustment	(184,016)	(356,308)	(153,139)	(297,169)
Interest on leases(i)	(128,536)	(251,996)	(115,227)	(218,992)
Charges on debentures	(125,579)	(262,269)	(121,859)	(222,087)
Interest, charges and bank fees	(23,490)	(61,459)	(32,232)	(50,021)
Charges on borrowings	-	-	(52)	(52)
Interest on payables to subsidiary's shareholder	(724)	(1,061)	(466)	(872)
Monetary variations	(237)	(300)	-	-
Amortization of transaction costs	(1,917)	(4,133)	(2,445)	(4,828)
Total finance costs	**(464,499)**	**(937,526)**	**(425,420)**	**(794,021)**
Finance income (costs)	**(324,790)**	**(654,154)**	**(329,814)**	**(613,651)**

	Consolidated			
Finance income	**2nd Quarter/26**	**Jun/26**	**2nd Quarter/25**	**Jun/25**
			Restated	Restated
Present value adjustment	118,526	246,602	92,930	171,463
Short-term investment yields	3,436	6,187	12,582	15,331
Monetary variations	16,652	31,832	276	4,739
Discounts obtained	1,208	1,332	425	783
Other income	1,883	2,147	189	258
Total finance income	**141,705**	**288,100**	**106,402**	**192,574**
Finance costs	**2nd Quarter/26**	**Jun/26**	**2nd Quarter/25**	**Jun/25**
			Restated	Restated
Present value adjustment	(184,016)	(356,308)	(153,139)	(297,168)
Interest on leases[i]	(128,536)	(251,996)	(115,227)	(218,992)
Charges on debentures	(125,579)	(262,269)	(121,859)	(222,087)
Interest, charges and bank fees	(23,615)	(61,391)	(32,430)	(50,354)
Charges on borrowings	-	-	(52)	(52)
Interest on payables to subsidiary's shareholder	(724)	(1,061)	(466)	(872)
Monetary variations	(947)	(1,181)	-	(1)
Amortization of transaction costs	(1,917)	(4,133)	(2,445)	(4,828)
Discounts granted	(72)	(131)	(37)	(71)
Total finance costs	**(465,406)**	**(938,470)**	**(425,655)**	**(794,425)**
Finance income (costs)	**(323,701)**	**(650,370)**	**(319,253)**	**(601,851)**

(i) Interest on leases is shown net of PIS and COFINS.

(All amounts in thousands of reais unless otherwise stated)

26.Financial instruments and risk management policy

26.1. Financial instruments by category

	Parent Company		Consolidated	
Financial instruments items	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
Assets				
At amortized cost				
Cash and cash equivalents (Note 5)	322,902	296,965	536,501	509,619
Trade receivables (Note 7)	2,977,266	2,757,988	3,095,749	3,400,585
Other current assets	1,504,135	689,044	1,483,484	743,571
Judicial deposits (Note 17)	68,644	66,196	68,680	301,319
Related parties	98,182	96,371	-	89,095
Subtotal	**4,971,129**	**3,906,564**	**5,184,414**	**5,044,189**
Measured at Fair Value Through Profit or Loss				
Held-to-maturity investments (Note 6)	28,624	28,112	116,449	19,120
Subtotal	**28,624**	**28,112**	**116,449**	**19,120**
Total assets	**4,999,753**	**3,934,676**	**5,300,863**	**5,063,309**
Liabilities				
Liabilities at fair value through profit or loss				
Suppliers - FIDC (Note 15)	-	-	243,938	228,549
Payables to subsidiary's shareholder	16,578	15,518	16,578	15,518
Subtotal	**16,578**	**15,518**	**260,516**	**244,067**
Other liabilities				
At amortized cost				
Suppliers	6,250,944	6,425,749	6,120,777	6,680,650
Borrowings (Note 16)	3,452,649	3,867,755	3,452,649	3,867,755
Other liabilities	468,374	483,977	635,192	578,055
Leases payable	5,139,174	4,959,231	5,140,386	4,966,312
Related parties	20,519	22,366	-	22,366
Subtotal	**15,331,660**	**15,759,078**	**15,349,004**	**16,115,138**
Total liabilities	**15,348,238**	**15,774,596**	**15,609,520**	**16,359,205**

(All amounts in thousands of reais unless otherwise stated)

26.2. Financial risk management

The Group's activities expose it to a variety of financial risks: market risk, credit risk and liquidity risk. The Group's risk management program focuses on the unpredictability of financial and operational markets and seeks to minimize potential adverse effects on the Group's financial performance.

The Board of Directors provides principles for overall risk management, as well as written policies covering specific areas, such as interest rate risk, credit risk, use of non-derivative financial instruments and investment of surplus cash.

(a) Market risk

Foreign exchange risk

The Company's assets and liabilities are mainly carried out in Brazilian reais (R$), and there is no risk due to exchange rate variations. During 2025, all foreign currency loans were fully repaid.

Interest rate risk

The Company's borrowings are pegged to the CDI plus bank spread. Financial investments are entered into based on the CDI variations, which does not result in higher interest rate risk since these variations are not significant. Management understands that there is a low risk of significant changes in profit or loss or in cash flows.

(b) Credit risk

Credit risk arises from financial assets, i.e. cash and cash equivalents, short-term investments and trade receivables. Cash and cash equivalents and short-term investments are maintained with sound financial institutions.

The risk ratings of the cash equivalents are in accordance with the main risk rating agencies, according to the table below:

	Parent Company		Consolidated	
Risk rating	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
Rating - National scale				
brAAA	40,565	3,047	251,643	196,293
brAA+	7,768	12,196	9,911	14,285
brA	272	125	272	125
(*) n/a - Cash and automatic investments	274,297	281,597	274,675	298,916
Total - National scale	**322,902**	**296,965**	**536,501**	**509,619**

(*) Not applicable, since there is no risk rating for cash, automatic investments and investment funds.

The granting of credit on sales of goods follows a policy that aims at minimizing defaults. For the period ended June 30, 2026, credit sales represented 77% (74% in 2025) for the Parent Company and 77% (77% in 2025) for the Consolidated accounts, of which 71% (73% in 2025) for the Parent Company and 71% (64% in 2025) for the Consolidated accounts related to credit card sales which, based on the history of losses, posed an extremely low risk. The other 29% (27% in 2025) for the Parent Company and 29% (36% in 2025) for the Consolidated accounts refer substantially to credits from Medicine Benefit Programs ("PBMs") and special plans that pose a low risk, due to customer selectivity.

(All amounts in thousands of reais unless otherwise stated)

(c) Liquidity risk

The Group's management continuously monitors forecasts of the Company's liquidity requirements, in order to ensure that it has sufficient cash to meet operational needs. The Group invests its surplus cash in financial assets with appropriate maturities to provide the liquidity necessary to honor its obligations.

(d) Sensitivity analysis

The Company prepares a sensitivity analysis of financial instruments indexed to interest rates to which the Company is exposed.

According to Management's assessment, the most likely scenario considers a 0.50% reduction in the benchmark interest rate over the next six months and the resulting impacts on revenue and expenses. In addition, another scenario is presented to illustrate a 25% change in the risk variable under consideration (Scenario II), as shown below:

	Parent Company		
		Effect on profit or loss and equity	
Operation	**Notional amount**	**Scenario I (probable)**	**Scenario II - 25%**
Short-term investments - CDI	109,284	(546)	(410)
Revenue		**(546)**	**(410)**
Borrowings - CDI	3,452,649	17,263	12,947
Expense		**17,263**	**12,947**
Effect on profit or loss		**16,717**	**12,537**

	Consolidated		
		Effect on profit or loss and equity	
Operation	**Notional amount**	**Scenario I (probable)**	**Scenario II - 25%**
Short-term investments - CDI	309,096	(1,545)	(1,159)
Revenue		**(1,545)**	**(1,159)**
Borrowings - CDI	3,452,649	17,263	12,947
Expense		**17,263**	**12,947**
Effect on profit or loss		**15,718**	**11,788**

(e) Capital management

The Group's objective relating to capital management is to maintain the Group's investment capacity, thus allowing it to grow its business and provide proper returns for shareholders.

The Group has adopted a policy of not leveraging its capital structure with borrowings, except for long-term credit facilities of debentures at interest rates that are commensurate with the Group's profit levels.

Accordingly, this ratio corresponds to the net debt expressed as a percentage of total capital. The net debt, in turn, corresponds to total borrowings less cash and cash equivalents. The total capital is calculated through the sum of the equity, as shown in the individual and consolidated balance sheet, and the net debt, as presented below:

	Parent Company		Consolidated	
Capital management items	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
Short- and long-term borrowings	3,452,649	3,867,755	3,452,649	3,867,755
(-) Cash and cash equivalents	(322,902)	(296,965)	(536,501)	(509,619)
Net debt	**3,129,747**	**3,570,790**	**2,916,148**	**3,358,136**
Equity attributable to the shareholders of the parent	7,290,780	7,322,129	7,290,780	7,322,129
Noncontrolling interests	-	-	-	13,839
Total equity	**7,290,780**	**7,322,129**	**7,290,780**	**7,335,968**
Total capital	**10,420,527**	**10,892,919**	**10,206,928**	**10,694,104**
Gearing ratio (%)	**30.03%**	**32.78%**	**28.57%**	**31.40%**

(All amounts in thousands of reais unless otherwise stated)

At June 30, 2026, the balance of lease liabilities for the Parent Company and Consolidated accounts amounted to R$ 5,139,174 and R$ 5,140,386 respectively. Considering the lease liability in the capital management calculation, the gearing ratio of the Company and the Group would be 53.22% for the Parent Company and 52.57% for the Consolidated accounts. Considering the balance of lease liabilities at the balance sheet dates in the capital management calculation, the gearing ratio of the Company and the Group would be as follows:

	Parent Company		Consolidated	
Adjusted net debt with lease liabilities	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**
Net debt	3,129,747	3,570,790	2,916,148	3,358,136
Lease liabilities	5,139,174	4,959,231	5,140,386	4,966,312
Adjusted net debt	**8,268,921**	**8,530,021**	**8,056,534**	**8,324,448**
Total equity	7,290,780	7,322,129	7,290,780	7,335,968
Total adjusted capital	**15,559,701**	**15,852,150**	**15,347,314**	**15,660,416**
Adjusted gearing ratio (%)	**53.14%**	**53.81%**	**52.49%**	**53.16%**

(f) Fair value estimation

The carrying values of financial investments in the balance sheet approximate their fair values since the remuneration rates are based on the CDI variation. The carrying values of trade receivables and payables are measured at amortized cost and are recorded at their original amount, less the provision for impairment and present value adjustment, when applicable. The carrying values are assumed to approximate their fair values, taking into consideration the realization of these balances and settlement terms not exceeding 61 days.

Borrowings are classified as financial liabilities not measured at fair value through profit or loss and are recognized using the amortized cost method, according to contractual conditions. The fair values of these instruments are considered substantially equivalent to their respective carrying amounts, since they refer to floating-rate financial instruments linked to the CDI, plus spreads consistent with prevailing market rates. Any differences between the estimated fair values and the carrying amounts are considered immaterial.

At June 30, 2026, the Group had no material assets and liabilities measured at fair value at Level 2 in the fair value hierarchy.

The following table presents the balances in Level 1 instruments for the period ended June 30, 2026:

	Parent Company	
Assets	**Jun/26**	**Dec/25**
RD Fundo de Investimento em Direitos Creditórios Corporativos	28,624	28,112
Total	**28,624**	**28,112**

	Consolidated	
Liabilities	**Jun/26**	**Dec/25**
Suppliers - FIDC	243,938	228,549
Total	**243,938**	**228,549**

The following table presents the changes in Level 3 instruments for the period ended June 30, 2026:

	Parent Company/Consolidated	
	Payables to subsidiary's shareholder	
Changes in payables to subsidiary's shareholder	**Jun/26**	**Dec/25**
Balance at January 1	15,518	13,573
Expenses recognized in the statement of income	1,060	1,945
Closing balance	16,578	15,518
Total expenses for the period recognized in the statement of income	**1,060**	**1,945**
Changes in unrealized expenses for the period included in the statement of income	**1,060**	**1,945**

(All amounts in thousands of reais unless otherwise stated)

27.Transactions with related parties

		Parent Company		Consolidated		Parent Company		Consolidated	
		Assets				Transacted amount			
Related parties	**Relationship**	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**	**Jun/26**	**Jun/25**	**Jun/26**	**Jun/25**
Current assets									
Receivables									
Special plans (i)									
4Bio Medicamentos Ltda.	Subsidiary	-	37	-	-	157	281	-	-
Regimar Comercial S.A.	Shareholder/Family	-	22	-	22	12	51	12	51
Impulso	Subsidiary	13	4	-	-	25	27	-	-
Amplisoftware Tecnologia Ltda.	Subsidiary	-	1	-	-	-	-	-	-
Labi Exames S.A.	Associate	-	3	-	3	-	-	-	-
Heliomar Ltda.	Shareholder/Board Member	-	-	-	-	11	6	11	6
Healthbit Performasys Tecnologia	Subsidiary	12	-	-	-	-	-	-	-
Advances to suppliers									
Cfly Consultoria e Gestão Empresarial Ltda.(ii)	Shareholder/Family	813	2,337	813	-	5,639	2,700	5,639	2,700
Ribeiro Filho, Pires Oliveira Dias e Freire Advogados(iii)	Shareholder/Family	-	-	-	-	38	77	38	77
Other receivables									
Rodrigo Wright Pipponzi (Mol Impacto)(vi)	Shareholder/Family	294	165	294	165	245	84	245	84
Subtotal (a)		**1,132**	**2,569**	**1,107**	**190**	**6,127**	**3,226**	**5,945**	**2,918**
Other receivables									
Stix Fidelidade e Inteligência S.A. (vii)	Subsidiary	93,435	89,095	-	89,095	23,290	10,829	-	10,829
Impulso (xi)	Subsidiary	4,732	4,868	-	-	31,079	-	-	-
ZTO Tecnologia e Serviços de Informação na Internet Ltda. ("Manipulação Raia Drogasil")(ix)	Subsidiary	15	13	-	-	72	89	-	-
4Bio Medicamentos S.A. (iv)	Subsidiary	-	2,395	-	-	7,571	-		-
Subtotal		**98,182**	**96,371**	**-**	**89,095**	**62,012**	**10,918**	**-**	**10,829**
Total current assets		**98,182**	**96,371**	**-**	**89,095**	**62,012**	**10,918**	**-**	**10,829**
Non-current assets									
Loans									
Healthbit Performasys Tecnologia (iv)	Subsidiary	-	-	-	-	-	1	-	-
Total non-current assets		**-**	**-**	**-**	**-**	**-**	**1**	**-**	**-**
Total receivables from related parties		**99,314**	**98,940**	**1,107**	**89,285**	**68,139**	**14,145**	**5,945**	**13,747**

Transactions with related parties consist of transactions with the Company's shareholders and persons connected to them:

(All amounts in thousands of reais unless otherwise stated)

		Parent Company		Consolidated		Parent Company		Consolidated	
		Liabilities				Transacted amount			
Related parties	**Relationship**	**Jun/26**	**Dec/25**	**Jun/26**	**Dec/25**	**Jun/26**	**Jun/25**	**Jun/26**	**Jun/25**
Current liabilities									
Related parties									
Stix Fidelidade e Inteligência S.A. (vii)	Subsidiary	20,519	22,366	-	22,366	59,672	59,935	-	59,935
Subtotal		**20,519**	**22,366**	**-**	**22,366**	**59,672**	**59,935**	**-**	**59,935**
Payables									
Rentals (v)									
Heliomar Ltda.	Shareholder/Board Member	32	-	32	-	128	255	128	255
Antonio Carlos Pipponzi	Shareholder/Board Member	13	12	13	12	62	71	62	71
Rosalia Pipponzi Raia	Shareholder/Board Member	13	12	13	12	62	71	62	71
Cristiana Almeida Pipponzi	Shareholder/Board Member	4	4	4	4	21	24	21	24
André Almeida Pipponzi	Shareholder/Board Member	4	4	4	4	21	24	21	24
Marta Almeida Pipponzi	Shareholder/Board Member	4	4	4	4	21	24	21	24
Obligation the acquisition of investees (xiii)									
ZTO Tecnologia e Serviços de Informação na Internet Ltda. ("Manipulação Raia Drogasil")	Director(s)	-	13,545	-	-	-	-	-	-
Subtotal (a)		**70**	**13,581**	**70**	**36**	**315**	**469**	**315**	**469**
Service providers									
Impulso (xi)	Subsidiary	4,061	45	-	-	31,792	117	-	-
Amplisoftware Tecnologia Ltda. (x)	Subsidiary	618	338	-	-	3,459	1,039	-	-
Labi Exames S.A. (xii)	Associate	-	-	-	-	-	-	-	-
Ribeiro Filho, Pires Oliveira Dias e Freire Advogados (iii)	Shareholder/Family	637	532	637	532	2,380	1,788	2,380	1,788
Kymberg (xiv)	Subsidiary	70	258	-	-	578	-	-	-
Rodrigo Wright Pipponzi (Mol Impacto) (vi)	Shareholder/Family	80	-	80	-	13,263	11,534	13,263	11,534
Healthbit Performasys Tecnologia (iv)	Subsidiary	400	119	-	-	1,530	1,123	-	-
Healthbit Serviços Médicos Ltda. (iv)	Subsidiary	357	252	-	-	1,129	1,039	-	-
4Bio Medicamentos Ltda. (iv)	Subsidiary	-	63	-	-	246	60,078	-	-
Associação Obra do Berço(xv)	Shareholder/Family	-	-	-	-	80	261	80	261
Cfly Consultoria e Gestão Empresarial Ltda. (ii)	Family	412	3,228	412	3,228	4,126	2,778	4,126	2,778
Subtotal (a)		**6,635**	**4,835**	**1,129**	**3,760**	**58,583**	**79,757**	**19,849**	**16,361**
Total payables to related parties		**27,224**	**40,782**	**1,199**	**26,162**	**118,570**	**140,161**	**20,164**	**76,765**

(a) *The balances of receivables and payables with related parties, arising from commercial transactions between the Company and its Related Parties, are allocated by function, with transactions with the same characteristics carried out with third parties.*

Transactions with related parties, basically purchases and sales of products, were carried out at prices, terms and conditions usual in the market.

(i) Sales made by agreements whose transactions are carried out under commercial conditions equivalent to those adopted with other companies.

(ii) Services of aircraft operation owned by Raia Drogasil S.A., which will pay the operator a monthly remuneration for the services of operational advisory, compliance, finance, maintenance coordination and maintenance technical control.

(iii) Transaction related to legal advisory.

(iv) Balance related to intermediation of commissions on Raia Drogasil S.A. referrals.

(v) Transactions related to rental of commercial properties for the implementation of pharmacies.

(vi) The balances and transactions relate to service agreements for the development, creation and production of marketing materials for the institutional sales area, and the design of the Company's internal magazine.

(vii) Transactions related to trade receivables and suppliers referring to the Stix points program.

(viii) Loan transaction with subsidiary ZTO Tecnologia e Serviços de Informação na Internet Ltda - Manipulaê, which is updated by CDI + 1.45% p.a. The transaction was completed in 2024.

(ix) Provision of services related to health programs.

(x) The balances and transactions refer to the provision of services related to implementation of electronic medical records for physicians and systems in pharmacies so that customers are able to schedule exams and consultations in pharmacies.

(xi) Represents the reimbursement of the sharing of costs or expenses, such as consulting services and software licensing.

(xii) Provision of services related to tests.

(xiii) Obligation arising from the acquisition of the investee, with the amount classified as Accounts payable for acquisition of subsidiaries in the balance sheet.

(xiv) Transactions related to the purchase of Company brands medications.

(xv) Transactions relating to social projects.

We also inform that there are no additional transactions other than the amounts presented above and that the category of the related parties corresponds to the entity's key management personnel.

(b) Key management compensation

Key management includes the Officers, Directors and members of the Supervisory Board. The compensation paid or payable for services rendered is as follows:

(All amounts in thousands of reais unless otherwise stated)

	Parent Company		Consolidated	
Compensation items	**Jun/26**	**Jun/25**	**Jun/26**	**Jun/25**
Share-based payment	22,301	18,076	22,301	18,272
Bonuses and social charges	12,618	3,530	12,618	4,454
Subtotal bonuses and social charges	**34,919**	**21,606**	**34,919**	**22,726**
Fees and social charges	17,744	15,485	17,744	17,485
Fringe benefits	49	326	49	326
Total	**52,712**	**37,417**	**52,712**	**40,537**

The Company applied the requirements of NBC TG 05 (R3) - Related-Party Disclosures and also considered the guidance in CVM Circular Letter SNC/SEP 1/2021, observing qualitative aspects of related-party transaction, and concluded that there are no material impacts that require disclosure of additional information in the interim financial information.

28.Insurance coverage

The Group has adopted a policy of taking out insurance coverage at amounts deemed sufficient to cover any losses on assets or civil liability attributed to it taking into consideration the nature of its activities and the guidance of its insurance consultants.

Insurance coverage amounts to R$ 1,708,958,650, considering Operational Risks, Civil Liability, D&O, Cyber Risk, Transportation, Fleet, Aircraft and Environmental policies.

29.Non-cash transactions

At June 30, 2026, the Group's main non-transactions were:

a) part of the compensation of key management personnel associated with the restricted share plan (Note 27);
b) the installment purchase of fixed assets items in the amount of R$ 16,610 (R$ 25,576 - Dec/25).
c) Recognition of lease liability with a balancing item in right-of-use assets, with additions of new agreements in the amount of R$ 320,576 (R$ 292,671 - June/25) for the Parent Company and R$ 321,973 (R$ 294,185 – June/25) for the Consolidated accounts, remeasurements of R$ 368,050 (R$ 469,123 - June/25) for the Parent Company and R$ 368,268 (R$ 469,715 – June/25) for the Consolidated accounts, and termination of agreements in the amount of (R$ 14,427) ((R$ 34,435 - June/25) for the Parent Company and (R$ 14,427) ((R$ 34,454 - June/25) for the Consolidated accounts.
d) Recognition of impairment loss on the investment in 4Bio in the amount of R$ 202,796 (Note 30).

30.Discontinued operations – Sale of 4Bio

30.1 Sale of investee – 4Bio

On May 4, 2026, the Company and Health Ventures S.A., a direct subsidiary of Profarma Distribuidora de Produtos Farmacêuticos S.A., executed the closing agreement for the sale of 4Bio, following the fulfillment of all suspensive conditions set forth in the Share Purchase and Sale Agreement and Other Covenants. On that date, the Company received R$ 100,000 in cash, representing the up-front portion of the transaction, and became entitled to receive the remaining amount (note 1.1). The balance receivable for the sale is recognized under other receivables in the amount of R$ 715,056, net of the portion already received in cash.

As a result of the transaction, the Company has no longer consolidated the assets, liabilities, revenues and expenses of the investee since the date of loss of control (May 4, 2026), in conformity with the requirements of CPC 36 (R3) / IFRS 10 – Consolidated Financial Statements.

As of June 30, 2026, the Company measured the fair value of the asset held for sale as a result of this measurement and recorded an expense of R$ 202,796 due to an impairment loss:

(All amounts in thousands of reais unless otherwise stated)

Fair value of the transaction	Jun/26
Amount receivable in cash [1]	500,000
Amount receivable in cash [1]	100,000
Amount receivable related to working capital [2]	73,339
Judicial deposit (DIFAL) [3]	120,667
Selling price	**794,006**
Net assets	983,193
Goodwill on future profitability	12,907
Surplus values	702
Total investments (Note 10)	**996,802**
Impairment loss	**(202,796)**
Update of other receivables	15,792
Updated gain/(loss)	**(187,004)**
Impact on income tax - 34%	63,581
Impact on RD Saúde's result	**(123,423)**

[1] Six fixed installments totaling R$ 100,000, with one installment due upon completion of the transaction and five annual installments adjusted by the CDI.
[2] Payment of working capital to RD Saúde in the estimated amount of R$ 73,339.
[3] R$ 120,667 net of success fee of R$ 6,630 in connection with a judicial deposit related to ICMS-DIFAL recorded in 4Bio, to which the Company is entitled to receive payment as soon as the lawsuit is enforced.

30.2. Breakdown of discontinued operation amounts

The results of discontinued operations, which include the operations of the former subsidiary 4Bio, for the periods ended June 30, 2026, and 2025 are presented below:

	2nd Quarter/26	Jun/26[1]	2nd Quarter/25	Jun/25
Net sales revenue	266,358	1,042,014	756,420	1,534,466
Cost of sales and services	(247,241)	(968,837)	(691,577)	(1,408,405)
Gross profit	**19,117**	**73,177**	**64,843**	**126,061**
Operating (expenses) income				
Selling	(10,329)	(40,062)	(32,250)	(63,522)
General and administrative	(3,681)	(14,283)	(11,512)	(21,471)
Other operating income/(expenses)	(25)	(7,265)	(67)	11,783
	(14,035)	**(61,610)**	**(43,829)**	**(73,210)**
Operating profit before finance results	**5,082**	**11,567**	**21,014**	**52,851**
Finance income (costs)				
Finance income	11,274	38,351	28,009	46,291
Finance costs	(8,079)	(29,957)	(25,997)	(41,190)
	3,195	**8,394**	**2,012**	**5,101**
Profit before income tax and social contribution	**8,277**	**19,961**	**23,026**	**57,952**
Income tax and social contribution				
Current	-	-	32,478	25,083
Deferred	-	-	3,214	(1,547)
	-	-	35,692	23,536
Profit for the period	**8,277**	**19,961**	**58,718**	**81,488**

The accumulated balance includes the four-month period (January to April) related to the sale of 4Bio completed on May 4, 2026.

The net cash flows from the discontinued operation are presented below:

	Jun/26[1]	Jun/25
Operating activities	(20,052)	75,002
Investing activities	(1,928)	(2,775)
Financing activities	(893)	59,695
Net cash generated (used)	**(22,873)**	**131,922**

Voltar

Deloitte Touche Tohmatsu
Av. Dr. Chucri Zaidan, 1.240 -
4º ao 12º andares - Golden Tower
04711-130 - São Paulo - SP
Brasil

Tel.: + 55 (11) 5186-1000
Fax: + 55 (11) 5181-2911
www.deloitte.com.br

(Convenience Translation into English from the Original Previously Issued in Portuguese)

REPORT ON THE REVIEW OF INDIVIDUAL AND CONSOLIDATED INTERIM FINANCIAL INFORMATION

To the Shareholders and Management of
Raia Drogasil S.A.
São Paulo - SP

Introduction

We have reviewed the individual and consolidated interim financial information of Raia Drogasil S.A. (“Company”), included in the Quarterly Interim Financial Information Form (ITR), for the quarter ended
June 30, 2026, which comprises the balance sheet as at June 30, 2026, and the related statements of profit or loss for the three and six-month periods then ended and changes in shareholders’ equity and cash flows for the six-month period then ended, including the accompanying explanatory notes.

The Company's Management is responsible for the preparation of the individual and consolidated interim financial information in accordance with technical pronouncement CPC 21 (R1) - Interim Financial Reporting and international standard IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), as well as for the presentation of such information in conformity with the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of the Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and international standards on review of interim financial information (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical procedures and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion on the individual and consolidated interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the individual and consolidated interim financial information included in the aforementioned Quarterly Information has not been prepared, in all material respects, in accordance with technical pronouncement CPC 21 (R1) and international standard IAS 34, applicable to the preparation of Quarterly Information (ITR), and presented in compliance with the rules issued by the CVM.

Deloitte.

Deloitte Touche Tohmatsu
Av. Dr. Chucri Zaidan, 1.240 -
4º ao 12º andares - Golden Tower
04711-130 - São Paulo - SP
Brasil

Tel.: + 55 (11) 5186-1000
Fax: + 55 (11) 5181-2911
www.deloitte.com.br

Other matters

Statements of value added

The aforementioned quarterly information includes the individual and consolidated statements of value added (DVA) for the six-month period ended June 30, 2026, which were prepared under the responsibility of the Company's Management and presented as supplementary information for the purposes of international standard IAS 34. These statements were subject to review procedures performed together with the review of the Quarterly Information, with the objective of concluding whether they are reconciled with the interim financial information and the accounting records, as applicable, and whether their form and content are in accordance with the criteria defined technical pronouncement CPC 09 (R1) - Statement of Value Added. Based on our review, nothing has come to our attention that causes us to believe that these statements were not prepared, in all material respects, in accordance with the criteria defined in that standard and presented consistently with the individual and consolidated interim financial information taken as a whole.

The accompanying individual and consolidated interim financial information has been translated into English for the convenience of readers outside Brazil.

São Paulo, August 4, 2026

DELOITTE TOUCHE TOHMATSU
Auditores Independentes Ltda.

Natacha Rodrigues dos Santos
Engagement Partner

57729

In this section, pursuant to CVM Resolution 80/2022, we compare the pharmacies opening projections for the Company with the data on pharmacies openings actually conducted every year.

On July 28, 2016, we revised the prior projection of 165 openings in 2016 and 195 openings in 2017 to 200 pharmacies openings for both years. On October 27, 2021, we revised the prior projection of 240 openings in 2022 to 260 openings. On October 31, 2022, we revised the prior projection for the period from 2023 to 2025 from 240 openings per year to 260 openings per year. On November 8, 2023, we revised the prior projection of 260 gross openings per year in 2023, 2024 and 2025 to 270 openings in 2023 and between 280 and 300 gross openings per year for 2024 and 2025. On November 29, 2024, we revised the prior projection of 280 to 300 gross openings per year to 330 to 350 gross openings per year for 2025. For 2026, the Company projected gross openings between 330 and 350 units, according to the material fact notice published on December 1, 2025.

YEAR	PRIOR PROJECTION	CURRENT PROJECTION	ACTUAL ACCUMULATED
2016	165 openings	200 openings	212 openings
2017	195 openings	200 openings	210 openings
2018	-	240 openings	240 openings
2019	-	240 openings	240 openings
2020	-	240 openings	240 openings
2021	-	240 openings	240 openings
2022	240 openings	260 openings	260 openings
2023	260 openings	270 openings	270 openings
2024	260 openings	Between 280 and 300 openings	300 openings
2025	Between 280 and 300 openings	Between 330 and 350 openings	330 openings
2026	-	Between 330 and 350 openings	144 openings

To the Board of Directors and Shareholders

Raia Drogasil S.A.

The Company's Supervisory Board, in exercising its duties and legal responsibilities, has examined the Interim Financial Information for the six-month period ended June 30, 2026 and, based on the examinations performed and on clarifications provided by Management, and also considering the favorable Report on Special Review without exceptions, issued by the independent auditor Deloitte Touche Tohmatsu, the Supervisory Board members concluded that the documents above are fairly presented, in all material respects.

São Paulo, August 4, 2026.

Paulo Sérgio Buzaid Tohmé
Supervisory Board Member

Gilberto Lerio
Supervisory Board Member

Adeildo Paulino
Supervisory Board Member

Guilherme Bottrel Pereira Tostes
Supervisory Board Member

In accordance with article 25, paragraph 1, items V and VI, of CVM Instruction 480/09, the Company's officers represent that they have reviewed, discussed and agree with the Interim Financial Information for the six-month period ended June 30, 2026.

São Paulo, August 4, 2026.

Renato Cepollina Raduan
CEO

Marcello De Zagottis
COO

Antonio Carlos Coelho
Financial and Administrative Vice President

Melissa Teixeira Cabral
Pharmacy Operations Vice President

Fernando Kozel Varela
Digital Transformation Vice President

Juliana Lopes Marques Paixão
Commercial Vice President

Erika Vanessa do Amaral Petri
People, Culture and Sustainability Vice President

Bruno Wright Pipponzi
Health Business Vice President

Afonso Celso Florentino de Oliveira
Controlling and Technical Officer
CRC 1MG071304/O-7 'T' SP

In accordance with article 25, paragraph 1, items V and VI, of CVM Instruction 480/09, the Company's officers represent that they have reviewed, discussed and agree with the conclusions expressed in the favorable Auditor's Report without exceptions issued by the independent auditors for the six-month period ended June 30, 2026.

São Paulo, August 04, 2026.

Renato Cepollina Raduan
CEO

Marcello De Zagottis
COO

Antonio Carlos Coelho
Financial and Administrative Vice President

Melissa Teixeira Cabral
Pharmacy Operations Vice President

Fernando Kozel Varela
Digital Transformation Vice President

Juliana Lopes Marques Paixão
Commercial Vice President

Erika Vanessa do Amaral Petri
People, Culture and Sustainability Vice President

Bruno Wright Pipponzi
Health Business Vice President

Afonso Celso Florentino de Oliveira
Controlling and Technical Officer
CRC 1MG071304/O-7 'T' SP